
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="4DDE442B89B6C8031B442B004E907F6B.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12309150/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Liver International">
<meta name="citation_title" content="Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials">
<meta name="citation_author" content="Alessandro Mantovani">
<meta name="citation_author_institution" content="Metabolic Diseases Research Unit, IRCCS Sacro Cuore – Don Calabria Hospital, Negrar di Valpolicella, Italy">
<meta name="citation_author_institution" content="Department of Medicine, University of Verona, Verona, Italy">
<meta name="citation_author" content="Riccardo Morandin">
<meta name="citation_author_institution" content="Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy">
<meta name="citation_author" content="Veronica Fiorio">
<meta name="citation_author_institution" content="Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy">
<meta name="citation_author" content="Maria Giovanna Lando">
<meta name="citation_author_institution" content="Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy">
<meta name="citation_author" content="Norbert Stefan">
<meta name="citation_author_institution" content="Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology, University of Tübingen, Tübingen, Germany">
<meta name="citation_author_institution" content="Institute of Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich, Tübingen, Germany">
<meta name="citation_author" content="Herbert Tilg">
<meta name="citation_author_institution" content="Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University Innsbruck, Innsbruck, Austria">
<meta name="citation_author" content="Christopher D Byrne">
<meta name="citation_author_institution" content="National Institute for Health and Care Research, Southampton Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton, UK">
<meta name="citation_author" content="Giovanni Targher">
<meta name="citation_author_institution" content="Metabolic Diseases Research Unit, IRCCS Sacro Cuore – Don Calabria Hospital, Negrar di Valpolicella, Italy">
<meta name="citation_author_institution" content="Department of Medicine, University of Verona, Verona, Italy">
<meta name="citation_publication_date" content="2025 Jul 30">
<meta name="citation_volume" content="45">
<meta name="citation_issue" content="9">
<meta name="citation_firstpage" content="e70256">
<meta name="citation_doi" content="10.1111/liv.70256">
<meta name="citation_pmid" content="40736113">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12309150/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12309150/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12309150/pdf/LIV-45-0.pdf">
<meta name="description" content="There is uncertainty regarding the hepatic efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in metabolic dysfunction‐associated steatotic liver disease (MASLD) or steatohepatitis (MASH). We performed a meta‐analysis of randomised ...">
<meta name="og:title" content="Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="There is uncertainty regarding the hepatic efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in metabolic dysfunction‐associated steatotic liver disease (MASLD) or steatohepatitis (MASH). We performed a meta‐analysis of randomised ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12309150/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12309150">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1111/liv.70256"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/LIV-45-0.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12309150%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12309150/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12309150/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12309150/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1111/liv.70256" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Liver Int</button></div>. 2025 Jul 30;45(9):e70256. doi: <a href="https://doi.org/10.1111/liv.70256" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1111/liv.70256</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Liver%20Int%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liver%20Int%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Liver%20Int%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Liver%20Int%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mantovani%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Alessandro Mantovani</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Alessandro Mantovani</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Metabolic Diseases Research Unit, IRCCS Sacro Cuore – Don Calabria Hospital, Negrar di Valpolicella, Italy</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Medicine, University of Verona, Verona, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mantovani%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alessandro Mantovani</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Morandin%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Riccardo Morandin</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Riccardo Morandin</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Morandin%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Riccardo Morandin</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fiorio%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Veronica Fiorio</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Veronica Fiorio</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fiorio%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Veronica Fiorio</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lando%20MG%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Maria Giovanna Lando</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Maria Giovanna Lando</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lando%20MG%22%5BAuthor%5D" class="usa-link"><span class="name western">Maria Giovanna Lando</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Stefan%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Norbert Stefan</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Norbert Stefan</span></h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology, University of Tübingen, Tübingen, Germany</div>
<div class="p">
<sup>
<sup>5</sup>
</sup>Institute of Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich, Tübingen, Germany</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Stefan%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Norbert Stefan</span></a>
</div>
</div>
<sup>4,</sup><sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tilg%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Herbert Tilg</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Herbert Tilg</span></h3>
<div class="p">
<sup>
<sup>6</sup>
</sup>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University Innsbruck, Innsbruck, Austria</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tilg%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Herbert Tilg</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Byrne%20CD%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Christopher D Byrne</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Christopher D Byrne</span></h3>
<div class="p">
<sup>
<sup>7</sup>
</sup>National Institute for Health and Care Research, Southampton Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Byrne%20CD%22%5BAuthor%5D" class="usa-link"><span class="name western">Christopher D Byrne</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Targher%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Giovanni Targher</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Giovanni Targher</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Metabolic Diseases Research Unit, IRCCS Sacro Cuore – Don Calabria Hospital, Negrar di Valpolicella, Italy</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Medicine, University of Verona, Verona, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Targher%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Giovanni Targher</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="liv70256-aff-0001">
<sup>
<sup>1</sup>
</sup>Metabolic Diseases Research Unit, IRCCS Sacro Cuore – Don Calabria Hospital, Negrar di Valpolicella, Italy</div>
<div id="liv70256-aff-0002">
<sup>
<sup>2</sup>
</sup>Department of Medicine, University of Verona, Verona, Italy</div>
<div id="liv70256-aff-0003">
<sup>
<sup>3</sup>
</sup>Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy</div>
<div id="liv70256-aff-0004">
<sup>
<sup>4</sup>
</sup>Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology, University of Tübingen, Tübingen, Germany</div>
<div id="liv70256-aff-0005">
<sup>
<sup>5</sup>
</sup>Institute of Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich, Tübingen, Germany</div>
<div id="liv70256-aff-0006">
<sup>
<sup>6</sup>
</sup>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University Innsbruck, Innsbruck, Austria</div>
<div id="liv70256-aff-0007">
<sup>
<sup>7</sup>
</sup>National Institute for Health and Care Research, Southampton Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton, UK</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong>
 
Giovanni Targher (<span>giovanni.targher@univr.it</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jul 17; Received 2025 Jun 26; Accepted 2025 Jul 23; Issue date 2025 Sep.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Liver International</em> published by John Wiley &amp; Sons Ltd.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12309150  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40736113/" class="usa-link">40736113</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<section id="liv70256-sec-0001"><h3 class="pmc_sec_title">Background/Aims</h3>
<p>There is uncertainty regarding the hepatic efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in metabolic dysfunction‐associated steatotic liver disease (MASLD) or steatohepatitis (MASH). We performed a meta‐analysis of randomised controlled trials (RCTs) to examine the efficacy of GLP‐1RAs in treating MASLD or MASH.</p></section><section id="liv70256-sec-0002"><h3 class="pmc_sec_title">Methods</h3>
<p>We systematically searched three electronic databases from inception until April 2025 to identify RCTs examining the efficacy of GLP‐1RAs for the treatment of MASLD or MASH. The outcome measures included MASH resolution without worsening of fibrosis or improvement in at least one stage of fibrosis without worsening of MASH, along with reductions in liver fat content measured using magnetic resonance‐based techniques. Meta‐analysis was conducted using random‐effects models.</p></section><section id="liv70256-sec-0003"><h3 class="pmc_sec_title">Results</h3>
<p>We identified 13 phase 2 or phase 3 RCTs (1811 participants). These trials diagnosed MASLD or MASH through liver biopsy (<em>n</em> = 4) or magnetic resonance‐based techniques (<em>n</em> = 9). Regardless of diabetes status, among individuals with MASH and moderate‐to‐advanced fibrosis, GLP‐1RAs (especially semaglutide 2.4 mg/week) for up to 72 weeks were superior to placebo in achieving MASH resolution (<em>n</em> = 3 RCTs; pooled random‐effects odds ratio 3.48, 95% CI 2.69–4.51; <em>I</em>
<sup>2</sup> = 0%), and in improving liver fibrosis (pooled odds ratio 1.79, 95% CI 1.37–2.35; <em>I</em>
<sup>2</sup> = 0%). Among individuals with MASH‐related compensated cirrhosis (<em>n</em> = 1 RCT available only), semaglutide did not lead to MASH resolution or improved fibrosis compared to placebo. Furthermore, GLP‐1RAs reduced magnetic resonance‐measured liver fat content (<em>n</em> = 9; pooled mean difference: −4.50%, 95% CI −6.60 to −2.40%; <em>I</em>
<sup>2</sup> = 95.9%).</p></section><section id="liv70256-sec-0004"><h3 class="pmc_sec_title">Conclusions</h3>
<p>GLP‐1RAs are a promising treatment option for MASLD or MASH. Further research is needed to evaluate the long‐term effects of GLP‐1RAs on liver‐related clinical events.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> GLP‐1 receptor agonists, incretin‐based therapy, metabolic dysfunction‐associated steatohepatitis, metabolic dysfunction‐associated steatotic liver disease</p></section></section><section class="abstract" id="LIV70256-abs-5001"><h2>Summary</h2>
<ul id="liv70256-list-0001" class="list" style="list-style-type:disc">
<li id="liv70256-li-0001"><p>In this comprehensive meta‐analysis, we examined published data from randomised controlled trials evaluating the efficacy of GLP‐1 receptor agonists for the treatment of MASLD or MASH in individuals with or without type 2 diabetes.</p></li>
<li id="liv70256-li-0002"><p>GLP‐1 receptor agonists are a promising therapeutic option for MASLD or MASH. Further studies are required to examine the long‐term effects of these drugs on the risk of developing liver‐related clinical events.</p></li>
</ul></section><section id="liv70256-sec-0005"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as non‐alcoholic fatty liver disease, has become the leading cause of chronic liver diseases worldwide [<a href="#liv70256-bib-0001" class="usa-link" aria-describedby="liv70256-bib-0001">1</a>, <a href="#liv70256-bib-0002" class="usa-link" aria-describedby="liv70256-bib-0002">2</a>]. The global prevalence of MASLD is estimated to be approximately 30%–40% among adults in the general population, ~60%–70% in individuals with type 2 diabetes mellitus (T2DM), and ~70%–80% in persons with obesity [<a href="#liv70256-bib-0001" class="usa-link" aria-describedby="liv70256-bib-0001">1</a>, <a href="#liv70256-bib-0002" class="usa-link" aria-describedby="liv70256-bib-0002">2</a>].</p>
<p>MASLD is a multisystem disease that creates a challenging therapeutic landscape in which pharmacotherapy must address both systemic metabolic dysfunction and liver disease to reduce the risk of developing serious liver‐related complications (such as cirrhosis, hepatic decompensation events, and hepatocellular carcinoma) and extrahepatic cardiometabolic outcomes (cardiovascular disease, chronic kidney disease, and new‐onset T2DM) [<a href="#liv70256-bib-0003" class="usa-link" aria-describedby="liv70256-bib-0003">3</a>, <a href="#liv70256-bib-0004" class="usa-link" aria-describedby="liv70256-bib-0004">4</a>, <a href="#liv70256-bib-0005" class="usa-link" aria-describedby="liv70256-bib-0005">5</a>].</p>
<p>In March 2024, resmetirom (a liver‐directed thyroid hormone receptor beta‐selective agonist) became the first drug to receive conditional approval from the US Food and Drug Administration for treating adults with non‐cirrhotic metabolic dysfunction‐associated steatohepatitis (MASH) and moderate‐to‐advanced liver fibrosis [<a href="#liv70256-bib-0006" class="usa-link" aria-describedby="liv70256-bib-0006">6</a>, <a href="#liv70256-bib-0007" class="usa-link" aria-describedby="liv70256-bib-0007">7</a>]. However, resmetirom has a neutral impact on body weight and insulin resistance, and its long‐term effect on the risk of major adverse cardiovascular events is currently unknown [<a href="#liv70256-bib-0008" class="usa-link" aria-describedby="liv70256-bib-0008">8</a>]. Furthermore, the relatively limited efficacy of resmetirom in improving liver fibrosis and its restricted global availability since approval highlight the need for other therapeutic options for MASLD/MASH.</p>
<p>Since the pathogenesis of MASLD/MASH is closely linked to metabolic dysfunction and insulin resistance, and cardiovascular disease is the leading cause of death in people with MASLD/MASH [<a href="#liv70256-bib-0005" class="usa-link" aria-describedby="liv70256-bib-0005">5</a>], it is believed that agents improving the cardiometabolic risk profile could also improve MASLD/MASH‐related outcomes [<a href="#liv70256-bib-0004" class="usa-link" aria-describedby="liv70256-bib-0004">4</a>].</p>
<p>Large cardiovascular and renal outcome trials have demonstrated the effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in reducing the risk of overall mortality and adverse cardiovascular and renal outcomes [<a href="#liv70256-bib-0009" class="usa-link" aria-describedby="liv70256-bib-0009">9</a>, <a href="#liv70256-bib-0010" class="usa-link" aria-describedby="liv70256-bib-0010">10</a>, <a href="#liv70256-bib-0011" class="usa-link" aria-describedby="liv70256-bib-0011">11</a>, <a href="#liv70256-bib-0012" class="usa-link" aria-describedby="liv70256-bib-0012">12</a>]. Additionally, some meta‐analyses of Phase 2 placebo‐controlled or active‐comparator‐controlled randomised controlled trials (RCTs) have shown that GLP‐1RA treatment can reduce liver fat content (as measured by magnetic resonance‐based techniques) and is associated with histological resolution of MASH, although it does not show improvement in liver fibrosis in MASLD/MASH [<a href="#liv70256-bib-0013" class="usa-link" aria-describedby="liv70256-bib-0013">13</a>, <a href="#liv70256-bib-0014" class="usa-link" aria-describedby="liv70256-bib-0014">14</a>]. While the benefit of GLP‐1RAs on liver fibrosis—that is, the strongest histological predictor of mortality and liver‐related and extrahepatic complications in MASLD—remains uncertain, these findings support the use of GLP‐1RAs in people living with MASLD who have cardiometabolic risk factors.</p>
<p>Understanding the hepatic effectiveness of GLP‐1RAs on histological endpoints is critically important, given the increasing use of these antihyperglycaemic agents in populations at high risk for liver‐related and cardiometabolic outcomes. Results from long‐term Phase 3 placebo‐controlled RCTs assessing the efficacy of GLP‐1RAs are ongoing. Recently, Sanyal et al. reported results from part 1 of the ESSENCE trial, a Phase 3 placebo‐controlled randomised trial involving 800 adults with biopsy‐proven MASH and liver fibrosis. This RCT examined the 72‐week effect of once‐weekly subcutaneous semaglutide 2.4 mg versus placebo on MASH resolution without worsening of fibrosis and improvement in fibrosis without worsening of MASH [<a href="#liv70256-bib-0015" class="usa-link" aria-describedby="liv70256-bib-0015">15</a>].</p>
<p>Therefore, in this updated and comprehensive systematic review and meta‐analysis, we examined the published data from Phase 2 and Phase 3 RCTs that evaluate the efficacy of GLP‐1RAs for the treatment of MASLD or MASH in individuals with or without pre‐existing T2DM.</p></section><section id="liv70256-sec-0006"><h2 class="pmc_sec_title">2. Materials and Methods</h2>
<section id="liv70256-sec-0007"><h3 class="pmc_sec_title">2.1. Protocol Registration</h3>
<p>The protocol of the meta‐analysis was registered in advance on Open Science Framework registries (<a href="https://doi.org/10.17605/OSF.IO/HGVS4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.17605/OSF.IO/HGVS4</a>).</p></section><section id="liv70256-sec-0008"><h3 class="pmc_sec_title">2.2. Data Sources and Searches</h3>
<p>We conducted this systematic review and meta‐analysis following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. We systematically searched the PubMed, Web of Science, and <a href="http://clinicaltrials.gov" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">ClinicalTrials.gov</a> databases from their inception to April 30, 2025, to identify RCTs evaluating the efficacy of GLP‐1RAs in the treatment of MASLD or MASH. The primary search terms (based on both MeSH and free‐text terms) included “non‐alcoholic fatty liver disease” (OR “NAFLD” OR “non‐alcoholic steatohepatitis” OR “NASH”) OR “metabolic dysfunction‐associated steatotic liver disease” (OR “MASLD” OR “metabolic dysfunction‐associated steatohepatitis” OR “MASH”) OR “metabolic dysfunction‐associated fatty liver disease” (OR “MAFLD”) AND “glucagon‐like peptide‐1 receptor agonists” OR “GLP‐1 receptor agonists” OR “exenatide” OR “liraglutide” OR “lixisenatide” OR “albiglutide” OR “dulaglutide” OR “semaglutide”. Searches were limited to human studies without language restrictions.</p></section><section id="liv70256-sec-0009"><h3 class="pmc_sec_title">2.3. Inclusion and Exclusion Criteria</h3>
<p>Studies were included if they were Phase 2 or Phase 3 placebo‐controlled or active‐comparator‐controlled RCTs involving adult (≥ 18 years old) individuals with MASLD or MASH (regardless of their T2DM status) that examined the efficacy of GLP‐1RAs on MASLD or MASH. The diagnosis of MASLD/MASH was based on liver biopsy or magnetic resonance‐based techniques, such as magnetic resonance imaging‐proton density fat fraction (MRI‐PDFF) or magnetic resonance spectroscopy (MRS). Among the active‐comparator‐controlled RCTs, we included only trials with an active antihyperglycaemic drug as a control arm for comparison (specifically those involving participants with T2DM). We excluded active‐comparator‐controlled RCTs that had a control arm consisting of non‐antihyperglycaemic drugs tested for their potential hepatoprotective effects (e.g., fibroblast growth factor‐21 [FGF‐21] analogues, and farnesoid X receptor [FXR] agonists—see Table <a href="#liv70256-supitem-0001" class="usa-link">S1</a>). We also excluded RCTs using dual or triple incretin receptor agonists, such as tirzepatide, survodutide, cotadutide, efinopegdutide, pemvidutide or retatrutide. Additionally, we excluded RCTs in which the diagnosis of MASLD/MASH was based on methods other than liver biopsy or magnetic resonance‐based techniques. Finally, we excluded case reports, retrospective observational studies, and non‐randomised interventional studies.</p></section><section id="liv70256-sec-0010"><h3 class="pmc_sec_title">2.4. Data Extraction and Quality Assessment</h3>
<p>Two investigators (AM and GT) independently reviewed the titles and abstracts of all RCTs identified using the above‐mentioned inclusion criteria. Each RCT that met the initial inclusion criteria underwent a full‐text review by both investigators independently. Any disagreements about the inclusion of studies were resolved by a third independent investigator (RM).</p>
<p>For each eligible RCT, we extracted data on the publication year, study country, sample size, participant characteristics (i.e., age, sex, ethnicity, Body Mass Index [BMI], pre‐existing T2DM, and serum liver enzyme levels), follow‐up duration, type of intervention, dosages of GLP‐1RAs or active drug comparators, and methods used for diagnosing MASLD/MASH.</p>
<p>The risk of bias for each eligible RCT was assessed using the Cochrane Collaboration tool by two independent authors (AM and GT). Any disagreements in scoring were reviewed, and a consensus was reached after discussion. The Cochrane Collaboration's tool assesses seven potential sources of bias: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias. For each of these domains, we categorised each eligible RCT into three levels: low, unclear or high risk of bias [<a href="#liv70256-bib-0016" class="usa-link" aria-describedby="liv70256-bib-0016">16</a>].</p></section><section id="liv70256-sec-0011"><h3 class="pmc_sec_title">2.5. Data Synthesis and Analysis</h3>
<p>The primary outcome measures were changes in the percentage of resolution of MASH without worsening liver fibrosis or an improvement in at least one stage of liver fibrosis without worsening of MASH. As secondary outcome measures, we collected data on changes in the absolute percentage of liver fat content using magnetic resonance techniques, as well as changes in mean post‐treatment values of serum liver enzyme levels, haemoglobin A1c and body weight.</p>
<p>For each RCT, the effect sizes of the primary outcome measures between participants randomly assigned to GLP‐1RA treatment and those assigned to placebo or reference therapy are presented as odds ratios (OR) and 95% confidence intervals (CI) for histological resolution of MASH or ≥ 1‐stage fibrosis improvement using both fixed‐ and random‐effect models. For changes in liver fat content (assessed by MRI‐based techniques), serum liver enzyme levels, haemoglobin A1c and body weight, the effect sizes are presented as mean differences (MD) and 95% CIs [<a href="#liv70256-bib-0017" class="usa-link" aria-describedby="liv70256-bib-0017">17</a>].</p>
<p>To evaluate the robustness of the observed associations, we conducted subgroup analyses based on baseline MASH‐related cirrhosis status (for RCTs using liver biopsy), study country, and type of comparator drug in the control arm (for RCTs using magnetic resonance imaging). We also performed univariable meta‐regression analyses to examine the potential effects of sex, age, body mass index, proportion of pre‐existing T2DM, and percentage changes in body weight during the trial on the observed GLP‐1RA‐induced reduction in the absolute percentage of liver fat content, as measured by MRI‐PDFF or MRS. We also tested for the possible excessive influence of individual studies using a meta‐analysis influence (leave‐one‐out) test, which eliminated each included RCT one at a time.</p>
<p>A visual inspection of the forest plots was conducted to evaluate the presence of statistical heterogeneity [<a href="#liv70256-bib-0017" class="usa-link" aria-describedby="liv70256-bib-0017">17</a>]. Statistical heterogeneity between studies was assessed using the chi‐square test and the <em>I</em>
<sup>2</sup>‐statistic, which estimates the percentage of variability between studies attributable to heterogeneity rather than chance alone [<a href="#liv70256-bib-0018" class="usa-link" aria-describedby="liv70256-bib-0018">18</a>]. The proportion of heterogeneity explained by between‐study variability was evaluated using the <em>I</em>
<sup>2</sup>‐statistic and considered low if the <em>I</em>
<sup>2</sup>‐index was 0% to 40%, or substantial if the <em>I</em>
<sup>2</sup>‐index was greater than 50% [<a href="#liv70256-bib-0018" class="usa-link" aria-describedby="liv70256-bib-0018">18</a>]. Publication bias was assessed through visual inspection of funnel plots and the Egger regression test [<a href="#liv70256-bib-0017" class="usa-link" aria-describedby="liv70256-bib-0017">17</a>].</p>
<p>All statistical tests were two‐sided, and a <em>p</em>‐value &lt; 0.05 was considered significant. We used R software (version 4.2.2/2022) for all statistical analyses with the following packages: <em>meta</em> (version 8.0–1) and <em>metafor</em> (version 4.6–0).</p></section><section id="liv70256-sec-0012"><h3 class="pmc_sec_title">2.6. Funding Source</h3>
<p>There was no funding source for this meta‐analysis.</p></section></section><section id="liv70256-sec-0013"><h2 class="pmc_sec_title">3. Results</h2>
<section id="liv70256-sec-0014"><h3 class="pmc_sec_title">3.1. Search Results and Study Characteristics</h3>
<p>The PRISMA flow diagram summarises the search and selection processes of the meta‐analysis (Figure <a href="#liv70256-supitem-0001" class="usa-link">S1</a>). After removing duplicates and screening titles and abstracts, we identified 16 studies from the PubMed, Scopus, and <a href="http://clinicaltrials.gov" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">ClinicalTrials.gov</a> databases for eligibility assessment. Subsequently, we excluded three studies due to unsatisfactory inclusion criteria, as specified in Table <a href="#liv70256-supitem-0001" class="usa-link">S1</a>. In total, 13 Phase 2 or Phase 3 RCTs met the eligibility criteria and were included in the final analysis [<a href="#liv70256-bib-0015" class="usa-link" aria-describedby="liv70256-bib-0015">15</a>, <a href="#liv70256-bib-0019" class="usa-link" aria-describedby="liv70256-bib-0019">19</a>, <a href="#liv70256-bib-0020" class="usa-link" aria-describedby="liv70256-bib-0020">20</a>, <a href="#liv70256-bib-0021" class="usa-link" aria-describedby="liv70256-bib-0021">21</a>, <a href="#liv70256-bib-0022" class="usa-link" aria-describedby="liv70256-bib-0022">22</a>, <a href="#liv70256-bib-0023" class="usa-link" aria-describedby="liv70256-bib-0023">23</a>, <a href="#liv70256-bib-0024" class="usa-link" aria-describedby="liv70256-bib-0024">24</a>, <a href="#liv70256-bib-0025" class="usa-link" aria-describedby="liv70256-bib-0025">25</a>, <a href="#liv70256-bib-0026" class="usa-link" aria-describedby="liv70256-bib-0026">26</a>, <a href="#liv70256-bib-0027" class="usa-link" aria-describedby="liv70256-bib-0027">27</a>, <a href="#liv70256-bib-0028" class="usa-link" aria-describedby="liv70256-bib-0028">28</a>, <a href="#liv70256-bib-0029" class="usa-link" aria-describedby="liv70256-bib-0029">29</a>, <a href="#liv70256-bib-0030" class="usa-link" aria-describedby="liv70256-bib-0030">30</a>].</p>
<p>The main characteristics of these 13 Phase 2 or Phase 3 RCTs (including eleven placebo‐controlled and two active‐comparator‐controlled trials) are detailed in Table <a href="#liv70256-tbl-0001" class="usa-link">1</a>. In total, 1811 middle‐aged overweight or obese individuals with MASLD or MASH were included in the study (&gt; 75% White individuals; 43% men; 64% had known T2DM; mean age 52 years; mean BMI 33 kg/m<sup>2</sup>; mean serum aspartate aminotransferase (AST) 38 IU/L; mean serum alanine aminotransferase (ALT) 49 IU/L). These participants were treated for a median duration of 26 weeks (interquartile range: 24–72 weeks), with a median of 72 weeks for RCTs with liver biopsy data and a median of 26 weeks for RCTs using MRI‐based data, respectively.</p>
<section class="tw xbox font-sm" id="liv70256-tbl-0001"><h4 class="obj_head">TABLE 1.</h4>
<div class="caption p"><p>Principal randomised clinical trials of GLP‐1RAs for the treatment of MASLD or MASH (eleven placebo‐controlled RCTs and two active‐comparator‐controlled RCTs) ordered by diagnostic methodology used for MASLD/MASH and publication year.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Author, Year, Country (Reference)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">RCT's characteristics</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Interventions (<em>n</em>), RCT's length</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Efficacy and/or effectiveness outcomes A vs. B (or vs. C or D)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Major adverse effects</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Magnetic resonance‐based clinical trials</strong>
</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Dutour et al. 2016; France [<a href="#liv70256-bib-0019" class="usa-link" aria-describedby="liv70256-bib-0019">19</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Patients with T2DM, 95% of whom had MASLD on MRS (phase 2a placebo‐controlled RCT)</p>
<p>White ethnicity: 100%; mean age: 52 years; male sex: 48%; BMI 36 kg/m<sup>2</sup>; HbA1c 7.5%; ALT 29 IU/L; AST 22 IU/L</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A: Exenatide 5–10 mcg bid (<em>n</em> = 22)</p>
<p>B: Placebo (<em>n</em> = 22)</p>
<p>Length: 26 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Exenatide and reference treatment led to a similar improvement in HbA1c (−0.7% ± 0.3% vs. −0.7% ± 0.4%; <em>p</em> = 0.29)</p>
<p>Significant weight loss was observed in the exenatide group (−5.5 ± 1.2 kg vs. −0.2 ± 0.8 kg; <em>p</em> = 0.001 for difference between groups)</p>
<p>Exenatide induced a significant reduction in liver fat content, compared with the reference treatment (liver fat content: −23.8% ± 9.5% vs. +12.5% ± 9.6%, <em>p</em> = 0.007)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">Not reported</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Frossing et al. 2018; Denmark [<a href="#liv70256-bib-0020" class="usa-link" aria-describedby="liv70256-bib-0020">20</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Women without diabetes with polycystic ovary syndrome and MASLD on MRS (phase 2a placebo‐controlled RCT)</p>
<p>White ethnicity: 100%; mean age: 47 years; female sex: 100%; BMI 33 kg/m<sup>2</sup>
</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A. Liraglutide 1.8 mg/day (<em>n</em> = 48)</p>
<p>B. Placebo (<em>n</em> = 24)</p>
<p>Length: 26 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Liraglutide reduced body weight by 5.2 kg (−5.6% from baseline), liver fat content (on MR spectroscopy) by 44%, and the prevalence of MASLD by about two‐thirds (all <em>p</em> &lt; 0.01)</p>
<p>Liraglutide caused significantly larger reductions in fasting glucose (liraglutide vs. placebo, mean between‐group difference [95% CI], −0.24 [−0.44 to −0.04] mmol/L; mean HbA1c [95% CI], −1.38 [−2.48 to −0.28] mmol/mol)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">Nausea (79% liraglutide vs. 13% placebo) and constipation (26% liraglutide vs. 0% placebo) were the most prevalent adverse events</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Yan et al. 2019; China [<a href="#liv70256-bib-0021" class="usa-link" aria-describedby="liv70256-bib-0021">21</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Patients with T2DM and MASLD on MRI‐PDFF (phase 2a active drug‐controlled RCT)</p>
<p>Asian ethnicity: 100%; mean age: 44 years; male sex: 69%; BMI 29.8 kg/m<sup>2</sup>; HbA1c 7.7%; ALT 43 IU/L; AST 33 IU/L</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A. Liraglutide 1.8 mg/day (<em>n</em> = 24)</p>
<p>B. Insulin glargine 0.2 IU/kg/day (<em>n</em> = 24)</p>
<p>C. Sitagliptin 100 mg/day (<em>n</em> = 27)</p>
<p>Length: 26 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>In the liraglutide and sitagliptin groups, liver fat content significantly decreased from baseline to week 26 (liraglutide, 15.4% ± 5.6% to 12.5% ± 6.4%, <em>p</em> &lt; 0.001; and sitagliptin, 15.5% ± 5.6% to 11.7% ± 5.0%, <em>p</em> = 0.001) but not in the insulin glargine group</p>
<p>HbA1c decreased in all treatment groups (liraglutide, 7.8% ± 1.4% to 6.8% ± 1.7%, <em>p</em> &lt; 0.001; sitagliptin, 7.6% ± 0.9% to 6.6% ± 1.1%, <em>p</em> = 0.016; and insulin glargine, 7.7% ± 0.9% to 6.9% ± 1.1%, <em>p</em> = 0.013)</p>
<p>Body weight significantly decreased in the liraglutide and sitagliptin groups (but not in the insulin glargine group)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">Not reported</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Khoo et al. 2019; Singapore [<a href="#liv70256-bib-0022" class="usa-link" aria-describedby="liv70256-bib-0022">22</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Patients without diabetes with obesity and MASLD on MRI‐PDFF (phase 2a placebo‐controlled RCT)</p>
<p>Asian ethnicity: 100%; mean age: 41 years; male sex: 90%; BMI 33 kg/m<sup>2</sup>; ALT 88 IU/L; AST 48 IU/L</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A. Liraglutide 3.0 mg/day (<em>n</em> = 15)</p>
<p>B. Lifestyle intervention (diet+exercise) (<em>n</em> = 15)</p>
<p>Length: 26 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">The two treatment groups had significant (<em>p</em> &lt; 0.01) and similar reductions in liver fat content (−8.1 ± 13.2 vs. −7.0% ± 7.1%), serum ALT (−39 ± 35 vs. −26 ± 33 U/L) and body weight at 26 weeks</td>
<td align="center" valign="top" rowspan="1" colspan="1">Nausea (80% vs. 0%), abdominal discomfort (100% vs. 6.7%) and diarrhoea (33% vs. 0%) were more frequent in the liraglutide group than in placebo</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Liu et al. 2020; China [<a href="#liv70256-bib-0023" class="usa-link" aria-describedby="liv70256-bib-0023">23</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Patients with T2DM and MASLD on MRI‐PDFF (phase 2a active drug‐controlled RCT)</p>
<p>Asian ethnicity: 100%; mean age: 48 years; male sex: 50%; BMI 28 kg/m<sup>2</sup>; HbA1c 8.3%; ALT 38 IU/L; AST 28 IU/L</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A. Exenatide 5–10 mcg bid (<em>n</em> = 38)</p>
<p>B. Insulin glargine 0.1–0.3 IU/kg/day (<em>n</em> = 38)</p>
<p>Length: 24 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">With exenatide treatment, liver fat content was significantly reduced (Δliver fat: −17.6% ± 13%). Exenatide treatment also resulted in greater reductions in visceral adipose tissue decreased in the exenatide group (ΔVAT: −43.6 ± 68 cm<sup>2</sup>) compared to the control group, and in serum ALT, AST, GGT levels, BMI and waist circumference than in the control group</td>
<td align="center" valign="top" rowspan="1" colspan="1">The proportion of adverse events was comparable between the two groups (13.2% for exenatide vs. 15.8% for insulin glargine)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Bizino et al. 2020; Netherlands [<a href="#liv70256-bib-0024" class="usa-link" aria-describedby="liv70256-bib-0024">24</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Patients with T2DM and MASLD on MRS (phase 2a placebo‐controlled RCT)</p>
<p>White ethnicity: 100%; mean age: 60 years; male sex: 59%; BMI 32 kg/m<sup>2</sup>; HbA1c 8.3%; ALT 14 IU/L; AST 33 IU/L</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A. Liraglutide 1.8 mg/day (<em>n</em> = 23)</p>
<p>B. Placebo (<em>n</em> = 26)</p>
<p>Length: 26 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Change in liver fat content was not different between the groups (liraglutide 18.1% ± 11.2% to 12.0% ± 7.7%; placebo 18.4% ± 9.4% to 14.7% ± 10.0%; estimated treatment effect −2.1 [95% CI −5.3, 1.0]%)</p>
<p>Liraglutide vs. placebo significantly reduced body weight (liraglutide 98.4 ± 13.8 kg to 94.3 ± 14.9 kg; placebo 94.5 ± 13.1 kg to 93.9 ± 3.2 kg; estimated treatment effect −4.5 [95% CI −6.4, −2.6] kg)</p>
<p>Serum liver enzymes and HbA1c levels declined in both groups without a significant treatment effect of liraglutide vs. placebo (liraglutide HbA1c 8.4% ± 1.1% to 7.3% ± 1.2%; placebo HbA1c 8.2% ± 1.0% to 7.5% ± 0.7%)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">There were no serious drug‐related adverse events</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Kuchay et al. 2020; India [<a href="#liv70256-bib-0025" class="usa-link" aria-describedby="liv70256-bib-0025">25</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Patients with T2DM and MASLD on MRI‐PDFF (open‐label trial add‐on to usual care: the D‐LIFT trial)</p>
<p>Asian ethnicity: 100%; mean age: 47 years; male sex: 70%; BMI 29.7 kg/m<sup>2</sup>; HbA1c 8.4%; ALT 69 IU/L; AST 47 IU/L</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A. Dulaglutide 1.5 mg/week (<em>n</em> = 32)</p>
<p>B. Placebo (<em>n</em> = 32)</p>
<p>Length: 24 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Dulaglutide resulted in a control‐corrected absolute change in liver fat content of −3.5% (95% CI −6.6, −0.4; <em>p</em> = 0.025) and a relative change of −26.4% (−44.2, −8.6; <em>p</em> = 0.004)</p>
<p>Dulaglutide resulted in a significantly larger reduction in serum GGT levels (mean between‐group difference −13.1 U/L [95% CI −24.4, −1.8]; <em>p</em> = 0.025) and in non‐significant changes in serum AST and ALT levels</p>
<p>Absolute changes in liver stiffness on Fibroscan (liver stiffness: −1.31 kPa [−2.99, 0.37]; <em>p</em> = 0.12) were not significant when comparing the two groups</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">There were no serious drug‐related adverse events</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Guo et al. 2020; China [<a href="#liv70256-bib-0026" class="usa-link" aria-describedby="liv70256-bib-0026">26</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Patients with T2DM and MASLD on MRS (open‐label trial add‐on to usual care)</p>
<p>Asian ethnicity: 100%; mean age: 52 years; male sex: 60%; BMI 28.6 kg/m<sup>2</sup>; HbA1c 7.4%; ALT 32 IU/L; AST 28 IU/L</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A. Liraglutide 1.8 mg/day (<em>n</em> = 31)</p>
<p>B. Insulin glargine 0.1–0.3 IU/kg/day (<em>n</em> = 30)</p>
<p>C. Placebo (<em>n</em> = 30)</p>
<p>Length: 26 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Liraglutide resulted in a significant decrease in liver fat content compared to placebo (liraglutide: 26.4% ± 3.2% to 20.6% ± 3.9%; placebo: 25.8% ± 4.5% to 25.7% ± 3.6%, <em>p</em> &lt; 0.05)</p>
<p>There was also a decrease in liver fat content in the insulin glargine group, but it was not statistically significant from baseline to week 26</p>
<p>Dulaglutide resulted in significant reductions in body weight (including visceral adipose tissue) and serum ALT and AST levels</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">Nausea and vomiting (0% placebo vs. 6.7% insulin glargine vs. 25.8% liraglutide) were the most prevalent adverse events</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Flint et al. 2021; Germany [<a href="#liv70256-bib-0027" class="usa-link" aria-describedby="liv70256-bib-0027">27</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Patients with/without T2DM and with MASLD on MRI‐PDFF and MRI‐elastography (phase 2a placebo‐controlled RCT)</p>
<p>White ethnicity: 100%; mean age: 60 years; male sex: 70%; BMI 35 kg/m<sup>2</sup>; HbA1c 7.3% (for diabetics); ALT 37 IU/L; AST 30 IU/L</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A. Semaglutide 0.4 mg/day (<em>n</em> = 34)</p>
<p>B. Placebo (<em>n</em> = 33)</p>
<p>Length: 72 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>At week 72, reductions in liver fat content were significantly greater with semaglutide (estimated treatment ratio: 0.50 [0.39, 0.66], <em>p</em> &lt; 0.0001), and more subjects achieved ≥ 30% reduction in liver fat content with semaglutide at weeks 24, 48 and 72 (all <em>p</em> &lt; 0.001)</p>
<p>Changes from baseline in liver stiffness were not significantly different between semaglutide and placebo at week 72</p>
<p>Semaglutide decreased serum liver enzymes, HbA1c and body weight</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">Gastrointestinal AEs were reported by more patients in the semaglutide than the placebo group, with diarrhoea (30.3% vs. 24.2%) and nausea (30.3% vs. 9.1%) the most frequent</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Liver biopsy‐based clinical trials</strong>
</td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
<td align="center" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Armstrong et al. 2016; United Kingdom [<a href="#liv70256-bib-0028" class="usa-link" aria-describedby="liv70256-bib-0028">28</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Patients with MASH and fibrosis stages F2‐4 on liver biopsy (phase 2b placebo‐controlled RCT: the LEAN trial)</p>
<p>White ethnicity: 88%; mean age: 51 years; male sex: 60%; BMI 36 kg/m<sup>2</sup>; ALT 71 IU/L; AST 51 IU/L; fibrosis F3‐F4 (on histology) 52%; pre‐existing T2DM: 33%</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A. Liraglutide 1.8 mg/day (<em>n</em> = 26)</p>
<p>B. Placebo (<em>n</em> = 26)</p>
<p>Length: 48 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Histologic resolution of MASH in the liraglutide vs. placebo groups: 39% vs. 9%, <em>p</em> = 0.019</p>
<p>Change in histologic NAS score in the liraglutide vs. placebo groups: −1.3 vs. −0.8, <em>p</em> = 0.24</p>
<p>Change in fibrosis stage in the liraglutide vs. placebo groups: −0.2 vs. 0.2, <em>p</em> = 0.11</p>
<p>Fibrosis improvement in the liraglutide vs. placebo groups: 26% vs. 14%, <em>p</em> = 0.46</p>
<p>Fibrosis worsening in the liraglutide vs. placebo groups: 9% vs. 36%, <em>p</em> = 0.04</p>
<p>Change in serum ALT in the liraglutide vs. placebo groups: −26.6 vs. −10.2 UI/L, <em>p</em> = 0.16</p>
<p>Change in serum AST in the liraglutide vs. placebo groups: −27 vs. + 9 IU/L; <em>p</em> = 0.02</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">Moderate gastrointestinal disorders in the liraglutide vs. placebo: 81% vs. 65%. In particular, nausea (46% vs. 38%), diarrhoea (38% vs. 19%) and vomiting (19% vs. 12%) were the most frequent adverse events in the liraglutide group compared to placebo</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Newsome et al. 2021; International cohort of individuals from 16 countries [<a href="#liv70256-bib-0029" class="usa-link" aria-describedby="liv70256-bib-0029">29</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Patients with MASH and fibrosis (stages F1‐3) on liver biopsy (phase 2b placebo‐controlled RCT)</p>
<p>White ethnicity: 77%; mean age: 55 years; male sex: 41%; BMI 35.7 kg/m<sup>2</sup>; pre‐existing T2DM: 62% (HbA1c 7.3%); ALT 54 IU/L; AST 43 IU/L</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A. Semaglutide 0.1 mg/day (<em>n</em> = 80)</p>
<p>B. Semaglutide 0.2 mg/day (<em>n</em> = 78)</p>
<p>C. Semaglutide 0.4 mg/day (<em>n</em> = 82)</p>
<p>D. Placebo (<em>n</em> = 80)</p>
<p>Length: 72 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Percentage of patients in whom MASH resolution was achieved with no worsening of fibrosis was 40% in the 0.1‐mg group, 36% in the 0.2‐mg group, 59% in the 0.4‐mg group, and 17% in the placebo group (<em>p</em> &lt; 0.001 for semaglutide 0.4 mg vs. placebo)</p>
<p>Improvement in fibrosis stage occurred in 43% of the patients in the 0.4‐mg group and 33% of the patients in the placebo group (<em>p</em> = 0.48)</p>
<p>Treatment with semaglutide resulted in dose‐dependent reductions in serum ALT and AST levels</p>
<p>Mean percent weight loss was 13% in the 0.4‐mg group and 1% in the placebo group (<em>p</em> &lt; 0.001)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">The percentages of patients with nausea, constipation, decreased appetite, vomiting, and abdominal pain were higher in the semaglutide 0.4‐mg group than in the placebo group (nausea, 42% vs. 11%; constipation, 22% vs. 12%; decreased appetite, 22% vs. 5%; vomiting, 15% vs. 2%; and abdominal pain, 7% vs. 4%)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Loomba et al. 2023; International cohort of individuals from 38 centres in Europe and the USA [<a href="#liv70256-bib-0030" class="usa-link" aria-describedby="liv70256-bib-0030">30</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Patients with MASH‐related compensated cirrhosis (stage F4) on liver biopsy (phase 2b placebo‐controlled RCT)</p>
<p>White ethnicity: 87%; mean age: 59.5 years; male sex: 31%; BMI 34.9 kg/m<sup>2</sup>; pre‐existing T2DM: 75% (HbA1c 7.2%); ALT 42 IU/L; AST 44 IU/L</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A. Semaglutide 2.4 mg/week (<em>n</em> = 47)</p>
<p>B. Placebo (<em>n</em> = 24)</p>
<p>Length: 48 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>At week 48, there was no significant difference between the two groups in the proportion of patients with an improvement in liver fibrosis of one stage or more without worsening of MASH (11% in the semaglutide group vs. 29% in the placebo group); odds ratio 0.28 (95% CI 0.06–1.24; <em>p</em> = 0.087)</p>
<p>There was no significant difference between groups in the proportion of patients who achieved MASH resolution (<em>p</em> = 0<sub>·</sub>29)</p>
<p>Despite the lack of histological changes with semaglutide, improvements were seen in liver fat content by MRI‐PDFF as well as non‐invasive markers of liver fat and liver injury associated with fibrosis progression</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">Similar proportions of patients in each group reported adverse events. The most common adverse events were nausea (45% vs. 17%), diarrhoea (19% vs. 8%), and vomiting (17% vs. none)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Sanyal et al. 2025; International cohort of individuals from 37 countries [<a href="#liv70256-bib-0015" class="usa-link" aria-describedby="liv70256-bib-0015">15</a>]</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Patients with MASH and fibrosis (stages F2 or F3) on liver biopsy (phase 3 placebo‐controlled RCT: the ESSENCE trial)</p>
<p>White ethnicity: 67%; mean age: 56 years; male sex: 43%; BMI 34.6 kg/m<sup>2</sup>; pre‐existing T2DM: 55% (HbA1c 7.2%); ALT 68 IU/L; AST 53 IU/L</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>A. Semaglutide 2.4 mg/week (<em>n</em> = 534)</p>
<p>B. Placebo (<em>n</em> = 266)</p>
<p>Length: 72 weeks</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Percentage of patients in whom MASH resolution was achieved with no worsening of fibrosis was 62.9% in the semaglutide group and 34.3% in the placebo group (<em>p</em> &lt; 0.001 for semaglutide vs. placebo)</p>
<p>Improvement in at least one stage of liver fibrosis occurred in 36.8% of the patients in the semaglutide group and 22.4% of those in the placebo group (<em>p</em> &lt; 0.001)</p>
<p>Semaglutide resulted in significant reductions in serum ALT and AST levels and non‐invasive fibrosis tests, as well as body weight and HbA1c compared to placebo</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">Nausea (36% vs. 13%), diarrhoea (27% vs. 12%), constipation (22% vs. 8%), and vomiting (18.6% vs. 5.6%) were higher in the semaglutide group than in the placebo group</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/liv70256-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="liv70256-note-0002"><p>
<em>Note:</em> In most randomised clinical trials included, MASLD/MASH were originally labelled as NAFLD or NASH.</p></div>
<div class="fn" id="liv70256-note-0003"><p>Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma‐glutamyltransferase; MRS, magnetic resonance spectroscopy; MRI‐PDFF, magnetic resonance imaging‐proton density fat fraction; MASLD, metabolic dysfunction‐associated steatotic liver disease; MASH, metabolic dysfunction‐associated steatohepatitis; RCT, randomised controlled trial; T2DM, type 2 diabetes mellitus.</p></div>
</div></section><p>Participants who met the criteria were randomly assigned to receive subcutaneous exenatide (<em>n</em> = 2 RCTs), liraglutide (<em>n</em> = 6 RCTs), dulaglutide (<em>n</em> = 1 RCT), semaglutide (<em>n</em> = 4 RCTs), or placebo/reference therapy specifically to treat MASLD or MASH. The diagnosis of MASLD was based on liver biopsy in four RCTs that included individuals with MASH and liver fibrosis (stages F2 to F4), while the remaining nine RCTs utilised MRI‐based techniques (MRI‐PDFF or MRS). Most of these RCTs specifically included individuals with T2DM (<em>n</em> = 6 RCTs), while five RCTs included participants with and without T2DM, and two RCTs were conducted in individuals who did not have T2DM, particularly those with obesity or women with polycystic ovary syndrome. Two were active‐comparator‐controlled RCTs involving patients with T2DM that compared GLP‐1 RA use versus sitagliptin and/or insulin glargine. Three RCTs included multinational cohorts (recruited in Europe, the United States, and other countries), five RCTs were conducted in Asia (China, Singapore, and India), and five were conducted in Europe (the United Kingdom, France, Denmark, Germany, and the Netherlands). Among the eligible RCTs with available data on adverse effects, GLP‐1RAs were generally well‐tolerated and had a similar adverse event profile to either placebo or reference therapy, except for a higher frequency of gastro‐intestinal symptoms, such as nausea, vomiting, constipation, diarrhoea, or abdominal discomfort. However, these gastro‐intestinal symptoms were mainly transient and mild‐to‐moderate in severity across the included RCTs. According to the Cochrane Collaboration's tool, eligible RCTs were assessed to have a low risk of bias (<em>n</em> = 5) or a moderate risk of bias (<em>n</em> = 8); no studies were considered to have a high risk of bias (as illustrated in Table <a href="#liv70256-supitem-0001" class="usa-link">S2</a>).</p></section><section id="liv70256-sec-0015"><h3 class="pmc_sec_title">3.2. Effect of GLP‐1RAs on Liver Histological Endpoints</h3>
<p>Figure <a href="#liv70256-fig-0001" class="usa-link">1</a> shows the forest plot and pooled estimates of the effect of GLP‐1RAs on the histologic resolution of MASH without worsening fibrosis. These findings are based on four placebo‐controlled RCTs involving 1262 participants randomly assigned to placebo or treatment with liraglutide 1.8 mg/day, semaglutide 2.4 mg/week, or semaglutide at doses of 0.1, 0.2, and 0.4 mg/day administered subcutaneously. When analysing all these RCTs together, GLP‐1 RA treatment significantly increased the rate of MASH resolution compared to placebo (<em>n</em> = 4 RCTs; pooled random‐effects odds ratio 3.39, 95% CI 2.63–4.36, <em>p</em> &lt; 0.001; <em>I</em>
<sup>2</sup> = 0%). Notably, after stratifying RCTs for MASH‐related cirrhosis status at baseline, we found that in patients with MASH and liver fibrosis (stages F2 or F3), GLP‐1RA treatment for up to 72 weeks was superior to placebo in achieving MASH resolution without worsening of fibrosis (<em>n</em> = 3 RCTs; pooled odds ratio 3.48, 95% CI 2.69–4.51, <em>p</em> &lt; 0.001; <em>I</em>
<sup>2</sup> = 0%). This beneficial effect of GLP‐1RAs on MASH resolution remained significant even after excluding the Phase 3 RCT by Sanyal et al. (pooled odds ratio 4.07, 95% CI 2.44–6.79, <em>p</em> &lt; 0.001; <em>I</em>
<sup>2</sup> = 0%). Conversely, in patients with MASH‐related compensated cirrhosis (<em>n</em> = 1 RCT involving 71 individuals), once‐weekly semaglutide 2.4 mg for 48 weeks did not achieve MASH resolution compared to placebo (pooled odds ratio 1.96, 95% CI 0.62–6.23).</p>
<figure class="fig xbox font-sm" id="liv70256-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b5/12309150/b54ecac3b4e7/LIV-45-0-g001.jpg" loading="lazy" id="jats-graphic-1" height="319" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/liv70256-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Forest plot and pooled estimates of the effect of GLP‐1RAs on the histologic resolution of MASH without worsening of liver fibrosis, compared to placebo, in RCTs stratified by the presence of MASH‐related cirrhosis at baseline (<em>n</em> = 4 placebo‐controlled RCTs).</p></figcaption></figure><p>Figure <a href="#liv70256-fig-0002" class="usa-link">2</a> shows the forest plot and pooled estimates of the effect of GLP‐1RAs on the improvement of at least one stage of liver fibrosis without worsening of MASH. In patients with MASH and liver fibrosis, treatment with GLP‐1RAs (primarily semaglutide) for up to 72 weeks was more effective than placebo in improving liver fibrosis without worsening of MASH (pooled odds ratio 1.79, 95% CI 1.37–2.35, <em>p</em> &lt; 0.001; <em>I</em>
<sup>2</sup> = 0%). However, this beneficial effect of GLP‐1RAs on fibrosis improvement was lost after removing the Phase 3 RCT by Sanyal et al. from the analysis (pooled odds ratio 1.50, 95% CI 0.98–2.28, <em>p</em> = 0.062; <em>I</em>
<sup>2</sup> = 0%). In patients with MASH‐related compensated cirrhosis, treatment with semaglutide for 48 weeks did not lead to fibrosis improvement (pooled odds ratio 0.29, 95% CI 0.08–1.04).</p>
<figure class="fig xbox font-sm" id="liv70256-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b5/12309150/124e2e364d9a/LIV-45-0-g003.jpg" loading="lazy" id="jats-graphic-3" height="317" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/liv70256-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Forest plot and pooled estimates of the effect of GLP‐1RAs on improvement in ≥ 1‐stage liver fibrosis without worsening of MASH compared to placebo, in RCTs stratified by the presence of MASH‐related cirrhosis at baseline (<em>n</em> = 4 placebo‐controlled RCTs).</p></figcaption></figure></section><section id="liv70256-sec-0016"><h3 class="pmc_sec_title">3.3. Effect of GLP‐1RAs on MRI‐Assessed Liver Fat Content</h3>
<p>Figure <a href="#liv70256-fig-0003" class="usa-link">3</a> shows the forest plot and pooled estimates of the effects of GLP‐1RAs on liver fat content, assessed via MRI‐PDFF or MRS (<em>n</em> = 9 RCTs involving 499 individuals who were randomly assigned to either placebo/reference therapy or to exenatide 10 mcg/day, liraglutide 1.8 mg/day, dulaglutide 1.5 mg/week, or semaglutide at 0.4 mg/day subcutaneously). Compared to placebo or reference therapy, treatment with GLP‐1RAs for up to 26 weeks was associated with a significant reduction in the absolute percentage of liver fat content (pooled mean difference (MD): −4.50%, 95% CI −6.60 to −2.40%; <em>p</em> &lt; 0.001; <em>I</em>
<sup>2</sup> = 95.9%). This absolute percentage reduction corresponds to a decrease in the mean relative percentage change in liver fat content of −35% for GLP‐1RAs compared to −14% for placebo, respectively. Similar results were observed when we examined the effect of GLP‐1RAs on liver fat reduction in placebo‐controlled and active‐comparator‐controlled RCTs, separately.</p>
<figure class="fig xbox font-sm" id="liv70256-fig-0003"><h4 class="obj_head">FIGURE 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b5/12309150/0b0b7a45578c/LIV-45-0-g002.jpg" loading="lazy" id="jats-graphic-5" height="364" width="709" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/liv70256-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Forest plot and pooled estimates of the effect of GLP‐1RAs on the absolute percentage of liver fat content, assessed by magnetic resonance‐based techniques, in RCTs stratified by the type of comparator drug (<em>n</em> = 7 placebo‐controlled and <em>n</em> = 2 active‐comparator‐controlled trials).</p></figcaption></figure></section><section id="liv70256-sec-0017"><h3 class="pmc_sec_title">3.4. Effects of GLP‐1RAs on Serum Liver Enzymes, Haemoglobin A1c and Body Weight</h3>
<p>Figures <a href="#liv70256-supitem-0001" class="usa-link">S2–S4</a> show the forest plots and pooled estimates of the effect of GLP‐1RAs on mean post‐treatment values of serum liver enzymes. Compared to placebo or reference therapy, GLP‐1RA use was associated with significant reductions in circulating levels of ALT (pooled MD: −9.99 IU/L, 95% CI −16.8 to −3.18 IU/L), AST (pooled MD: −7.03 IU/L, 95% CI −13.43 to −0.63 IU/L) and gamma‐glutamyltransferase (GGT) (pooled MD: −18.29 IU/L, 95% CI −29.26 to −7.32 IU/L).</p>
<p>Figures <a href="#liv70256-supitem-0001" class="usa-link">S5</a> and <a href="#liv70256-supitem-0001" class="usa-link">S6</a> show the forest plots and pooled estimates of the effect of GLP‐1RAs on mean post‐treatment values of body weight and HbA1c levels. Compared to placebo/reference therapy, treatment with GLP‐1RAs was associated with significant reductions in body weight (pooled MD: −4.48 kg, 95% CI −6.08 to −2.88 kg, <em>p</em> &lt; 0.001) and HbA1c levels (pooled MD: −1.30%, 95% CI −1.69% to −0.91%).</p></section><section id="liv70256-sec-0018"><h3 class="pmc_sec_title">3.5. Subgroup and Meta‐Regression Analyses</h3>
<p>A subgroup analysis by study country revealed that the observed GLP‐1RA‐induced reduction in liver fat content (as measured with MRI‐based techniques) was consistent in RCTs conducted in both Europe and Asian countries (Figure <a href="#liv70256-supitem-0001" class="usa-link">S7</a>). We also conducted univariable meta‐regression analyses to explore the potential influence of moderator variables on the observed reduction in liver fat content, expressed as absolute percentage and measured by MRI‐PDFF or MRS (Figures <a href="#liv70256-supitem-0001" class="usa-link">S8–S12</a>). These meta‐regression analyses suggested that sex, age, BMI, pre‐existing T2DM, and percentage changes in body weight during the trial did not significantly affect the effect size for the GLP‐1RA‐induced reduction in liver fat content, although the influence of body weight change during the trial was marginally significant (<em>p</em> = 0.059). Finally, we also conducted a leave‐one‐out meta‐analysis to examine the influence of each RCT on the overall effect size estimate for hepatic histological endpoints and MRI‐measured liver fat content and to identify potential influential studies (Figure <a href="#liv70256-supitem-0001" class="usa-link">S13</a>).</p></section><section id="liv70256-sec-0019"><h3 class="pmc_sec_title">3.6. Publication Bias Testing</h3>
<p>As shown in Figures <a href="#liv70256-supitem-0001" class="usa-link">S14</a> and <a href="#liv70256-supitem-0001" class="usa-link">S15</a>, the funnel plots were quite symmetrical. The Egger's regression test did not indicate any statistically significant asymmetry in the funnel plots of the RCTs examining the effects of GLP‐1RAs on MASH resolution (<em>p</em> = 0.703) or improvement in liver fat content (<em>p</em> = 0.151), as evaluated by MRI‐based techniques. Although the number of RCTs included was fewer than 10, these results suggest that publication bias was low.</p></section></section><section id="liv70256-sec-0020"><h2 class="pmc_sec_title">4. Discussion</h2>
<p>To our knowledge, this is the largest and most comprehensive meta‐analysis of Phase 2 or Phase 3 RCTs that used GLP‐1RAs for the treatment of MASLD or MASH. The meta‐analysis incorporated 13 placebo‐controlled (<em>n</em> = 11) or active‐comparator‐controlled (<em>n</em> = 2) RCTs from different countries (including the recent Phase 3 ESSENCE trial) that aggregated data on 1811 middle‐aged individuals with overweight or obesity for whom the diagnosis of MASLD was based on magnetic resonance‐based techniques, and MASH±liver fibrosis was assessed histologically [<a href="#liv70256-bib-0015" class="usa-link" aria-describedby="liv70256-bib-0015">15</a>]. Most individuals included in these RCTs had comorbid T2DM, accounting for ~65% of participants.</p>
<p>The main and novel findings of this meta‐analysis indicate that among individuals with MASH and liver fibrosis (stages F2 or F3), treatment with GLP‐1RAs for up to 72 weeks was better than placebo in achieving MASH resolution without worsening of fibrosis (<em>n</em> = 3 placebo‐controlled RCTs; pooled odds ratio 3.48, 95% CI 2.69–4.51; <em>I</em>
<sup>2</sup> = 0%) and also in improving at least one stage of liver fibrosis without worsening of MASH (pooled odds ratio 1.79, 95% CI 1.37–2.35; <em>I</em>
<sup>2</sup> = 0%). In contrast, for individuals with MASH‐related compensated cirrhosis (only one small phase 2 RCT available), treatment with semaglutide for 48 weeks did not improve liver fibrosis or lead to MASH resolution compared with placebo. However, larger RCTs with longer follow‐up durations are needed to confirm this finding. Additionally, GLP‐1RA use for up to 26 weeks was associated with significant reductions in liver fat content, measured by MRI‐based techniques (<em>n</em> = 9 RCTs; pooled mean difference: −4.50%, 95% CI −6.60 to −2.40%; <em>p</em> &lt; 0.001), and in serum liver enzyme levels. The meta‐analysis also found that GLP‐1RA use was significantly associated with weight loss (~4.5 kg) and a decrease in haemoglobin A1c levels (−1.3% or −8 mmol/mol) compared to placebo. Our meta‐regression analyses also showed that sex, age, BMI and T2DM status at baseline, as well as changes in body weight during the trial (although this last factor was found to be marginally significant), did not influence the observed GLP‐1RA‐induced improvement in liver fat content. However, these latter results should be interpreted with caution, as fewer than 10 RCTs were included in meta‐regression analyses.</p>
<p>The evaluation of the RCTs included in the meta‐analysis reveals a paucity of large, high‐quality RCTs with a sufficiently long duration and liver biopsy data, which is the reference method for assessing drug‐induced resolution of MASH or ≥ 1‐stage liver fibrosis improvement. To date, only four placebo‐controlled RCTs (three Phase 2 trials and one Phase 3 trial) have examined the hepatic efficacy of GLP‐1RAs (subcutaneous liraglutide or semaglutide) on MASH resolution and fibrosis improvement. These are the two liver histological endpoints requested by the FDA for the conditional approval of a drug candidate for the treatment of MASH, and they are the histological features most closely associated with the risk of dying or developing liver‐related and extrahepatic complications in MASLD [<a href="#liv70256-bib-0004" class="usa-link" aria-describedby="liv70256-bib-0004">4</a>, <a href="#liv70256-bib-0031" class="usa-link" aria-describedby="liv70256-bib-0031">31</a>].</p>
<p>That said, compared to other previously published meta‐analyses of RCTs examining the effect of GLP‐1RAs in MASLD/MASH (including one from our group) [<a href="#liv70256-bib-0013" class="usa-link" aria-describedby="liv70256-bib-0013">13</a>, <a href="#liv70256-bib-0014" class="usa-link" aria-describedby="liv70256-bib-0014">14</a>, <a href="#liv70256-bib-0032" class="usa-link" aria-describedby="liv70256-bib-0032">32</a>, <a href="#liv70256-bib-0033" class="usa-link" aria-describedby="liv70256-bib-0033">33</a>, <a href="#liv70256-bib-0034" class="usa-link" aria-describedby="liv70256-bib-0034">34</a>], it should be noted that the inclusion of the recent Phase 3 ESSENCE trial, which compares once‐weekly subcutaneous semaglutide 2.4 mg versus placebo for 72 weeks in participants with MASH and fibrosis stages 2 or 3 [<a href="#liv70256-bib-0015" class="usa-link" aria-describedby="liv70256-bib-0015">15</a>], has allowed us to show, for the first time, a significant improvement in at least one stage of liver fibrosis without worsening of MASH. This finding has not been previously demonstrated in any earlier meta‐analysis of Phase 2 MASH clinical trials using GLP‐1RAs alone, or in other recently published meta‐analyses that included not only GLP‐1RAs but also dual or triple incretin receptor agonists, such as tirzepatide, survodutide, efinopegdutide, or retatrutide [<a href="#liv70256-bib-0035" class="usa-link" aria-describedby="liv70256-bib-0035">35</a>]. The benefit of GLP‐1RAs (primarily semaglutide 2.4 mg/week) on the severity of liver fibrosis is clinically relevant and is also supported by significant improvements in non‐invasive fibrosis tests (such as ELF score, serum PRO‐C3 levels, and liver stiffness by vibration‐controlled transient elastography). Long‐term data from part 2 of the ESSENCE trial are ongoing to evaluate the effect of semaglutide 2.4 mg weekly on the risk of liver‐related clinical events over 240 weeks [<a href="#liv70256-bib-0036" class="usa-link" aria-describedby="liv70256-bib-0036">36</a>].</p>
<p>Compelling evidence shows that GLP‐1RAs offer clinical benefits that extend beyond long‐term glycemic control. These antihyperglycemic agents provide significant advantages in reducing the risk of all‐cause mortality and adverse cardiovascular and renal complications for patients with T2DM and obesity [<a href="#liv70256-bib-0009" class="usa-link" aria-describedby="liv70256-bib-0009">9</a>, <a href="#liv70256-bib-0010" class="usa-link" aria-describedby="liv70256-bib-0010">10</a>, <a href="#liv70256-bib-0011" class="usa-link" aria-describedby="liv70256-bib-0011">11</a>, <a href="#liv70256-bib-0012" class="usa-link" aria-describedby="liv70256-bib-0012">12</a>]. These findings further support the long‐term use of GLP‐1RAs in individuals living with T2DM and MASLD.</p>
<p>The findings of this meta‐analysis may have significant clinical implications. From a clinical perspective, we believe that the evidence supporting the hepatic effectiveness of GLP‐1RAs in resolving MASH, along with the improvement in liver fibrosis, is clinically important, especially considering the growing burden of MASLD and MASH worldwide and the adverse effects of these conditions on the risk of long‐term liver‐related and extrahepatic cardiometabolic and malignant outcomes [<a href="#liv70256-bib-0003" class="usa-link" aria-describedby="liv70256-bib-0003">3</a>, <a href="#liv70256-bib-0004" class="usa-link" aria-describedby="liv70256-bib-0004">4</a>, <a href="#liv70256-bib-0005" class="usa-link" aria-describedby="liv70256-bib-0005">5</a>]. In these RCTs, GLP‐1RAs were generally well‐tolerated, with adverse event rates not exceeding those of the placebo, except for a higher frequency of transient, mild‐to‐moderate gastrointestinal disorders. Notably, real‐world retrospective observational cohort studies (involving about 1.5 million patients with T2DM) using an emulated target trial design have also shown that compared to DPP‐4 inhibitors or other antihyperglycaemic agents, the use of GLP‐1RAs is associated with a significantly lower risk of liver‐related clinical events, such as incident cirrhosis, hepatic decompensation events, or hepatocellular carcinoma [<a href="#liv70256-bib-0037" class="usa-link" aria-describedby="liv70256-bib-0037">37</a>]. GLP‐1RAs align with the American Diabetes Association recommendations as the preferred option for adults with T2DM and MASH, or those at high risk of liver fibrosis [<a href="#liv70256-bib-0038" class="usa-link" aria-describedby="liv70256-bib-0038">38</a>, <a href="#liv70256-bib-0039" class="usa-link" aria-describedby="liv70256-bib-0039">39</a>]. Other Phase 2 and Phase 3 MASH therapeutic trials are also ongoing, investigating the effects of tirzepatide (a dual GLP‐1/GIP receptor co‐agonist) and other dual or triple incretin receptor agonists on liver histological endpoints and long‐term liver‐related clinical events [<a href="#liv70256-bib-0040" class="usa-link" aria-describedby="liv70256-bib-0040">40</a>, <a href="#liv70256-bib-0041" class="usa-link" aria-describedby="liv70256-bib-0041">41</a>, <a href="#liv70256-bib-0042" class="usa-link" aria-describedby="liv70256-bib-0042">42</a>].</p>
<p>A detailed discussion of the potential mechanisms by which GLP‐1RAs could exert their beneficial effects on MASLD/MASH is beyond the scope of this meta‐analysis. Nonetheless, these mechanisms are complex and not fully understood. It is reasonable to assume that the hepatoprotective effects of GLP‐1RAs are multifactorial, resulting from their combined positive effects on hyperglycaemia, insulin resistance, and overweight/obesity, as well as their positive effects on the liver, which can be at least partly independent of weight loss [<a href="#liv70256-bib-0042" class="usa-link" aria-describedby="liv70256-bib-0042">42</a>, <a href="#liv70256-bib-0043" class="usa-link" aria-describedby="liv70256-bib-0043">43</a>].</p>
<p>The main strength of this study is its use of a systematic review method to identify all relevant RCTs (published up to April 30, 2025) that meet the predefined inclusion criteria. This provides the most current assessment of the hepatic effectiveness of GLP‐1RAs, including the newest MASH therapeutic trials (the ESSENCE trial). Additionally, most of the included RCTs used MRI‐PDFF or MRS, which are currently the two most accurate imaging techniques for measuring changes in liver fat content, although their accuracy in assessing MASH and liver fibrosis stage is somewhat limited [<a href="#liv70256-bib-0044" class="usa-link" aria-describedby="liv70256-bib-0044">44</a>]. Finally, the results of the four placebo‐controlled RCTs with liver biopsy data showed no heterogeneity among the studies included in the meta‐analysis (<em>I</em>
<sup>2</sup> = 0%), supporting the notion that the hepatic effects of GLP‐1RAs on MASH resolution and fibrosis improvement are consistently effective in a clinical context.</p>
<p>Our meta‐analysis has important limitations inherent in the included RCTs. First, as previously mentioned, most eligible RCTs had relatively small sample sizes and relatively short treatment durations. Second, only one Phase 3 placebo‐controlled RCT (the ESSENCE trial) with liver histological endpoints as the primary outcome was available for the meta‐analysis. Third, most RCTs enrolled overweight or obese individuals with MASLD and T2DM (predominantly of White race), highlighting the urgent need for RCTs involving people without T2DM and non‐obese individuals with MASLD from diverse ethnic backgrounds. Finally, because of significant sex‐related differences in the prevalence, risk factors, and clinical outcomes of MASLD/MASH [<a href="#liv70256-bib-0045" class="usa-link" aria-describedby="liv70256-bib-0045">45</a>], future adequately powered RCTs should be designed to evaluate sex‐related differences in the response rates of MASLD/MASH to GLP‐1RA treatment.</p>
<p>In conclusion, the results of this updated meta‐analysis strongly support the hepatic effectiveness of GLP‐1RAs (mainly semaglutide 2.4 mg/week) in reducing liver fat content, achieving resolution of MASH, and improving liver fibrosis in individuals with MASH and fibrosis, regardless of T2DM status. While we await results from Phase 3 randomised controlled trials designed to evaluate the long‐term benefits of GLP‐1RAs on liver‐related clinical events, these findings suggest that GLP‐1RAs are a suitable treatment option (either alone or combined with other liver‐directed pharmacotherapies, such as resmetirom, peroxisome proliferator‐activated‐receptor agonists, or FGF‐21 analogues) for individuals living with MASLD or MASH, especially among those who are obese or have T2DM.</p></section><section id="liv70256-sec-0022"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>A.M. and G.T. were involved in the conception of the study, as well as the analysis and interpretation of the results. G.T. wrote the first draft of the manuscript. A.M., R.M., V.F., M.G.L. and G.T. were involved in the conduct of the study and searched the published articles. N.S., H.T. and C.D.B. were involved in the interpretation of the results and contributed to the discussion. All authors edited, reviewed, and approved the final version of the manuscript. G.T. is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p></section><section id="liv70256-sec-0023"><h2 class="pmc_sec_title">Ethics Statement</h2>
<p>This study involves human participants but was not approved by an Ethics Committee(s) or Institutional Board(s). In fact, approval from an Ethics Committee is unnecessary because this is a meta‐analysis of published observational studies that have already obtained informed consent from participants and received ethical approval from their local Ethics committees.</p></section><section id="liv70256-sec-0021"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors did not report any disclosures related to this work. C.D.B. has received research grants from Echosens. C.D.B. is supported in part by the Southampton National Institute for Health Research (NIHR) Biomedical Research Centre (NIHR203319). N.S. received fees for consultancy and giving scientific talks from Allergan, AstraZeneca, Boehringer Ingelheim, Gilead, Genkyotex, GSK, Intercept Pharma, Lilly, Merck Sharpe &amp; Dohme, Novartis, Novo Nordisk, Pfizer, and Sanofi; and received research support from AstraZeneca, Sanofi, DSM. Nutritional Products, and Roche Diagnostics. G.T. is supported in part by grants from the University School of Medicine of Verona, Verona, Italy.</p></section><section id="sec24"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="liv70256-supitem-0001"><div class="caption p"><p>
<strong>Data S1:</strong> liv70256‐sup‐0001‐supinfo.pdf.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12309150/bin/LIV-45-0-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">LIV-45-0-s001.pdf</a><sup> (2MB, pdf) </sup>
</div></div></section></section><section id="liv70256-sec-26" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Open access publishing facilitated by Universita degli Studi di Verona, as part of the Wiley ‐ CRUI‐CARE agreement.</p></section><section id="notes1"><p>

Mantovani A., Morandin R., Fiorio V., et al., “Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials,” Liver International
45, no. 9 (2025): e70256, 10.1111/liv.70256.
</p>
<section id="liv70256-ntgp-0001" class="fn-group"><div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="liv70256-note-0001"><p>
<strong>Funding:</strong> The authors received no specific funding for this work.</p></div></div></section></section><section id="liv70256-sec-0025"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>The data that supports the findings of this study are available in the <a href="#liv70256-supitem-0001" class="usa-link">Supporting Information</a> of this article.</p></section><section id="liv70256-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="liv70256-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="liv70256-bib-0001">
<span class="label">1.</span><cite>
Younossi Z. M., Kalligeros M., and Henry L., “Epidemiology of Metabolic Dysfunction‐Associated Steatotic Liver Disease,” Clinical and Molecular Hepatology
31, no. Suppl (2025): S32–S50.
</cite> [<a href="https://doi.org/10.3350/cmh.2024.0431" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11925440/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39159948/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20and%20Molecular%20Hepatology&amp;title=Epidemiology%20of%20Metabolic%20Dysfunction%E2%80%90Associated%20Steatotic%20Liver%20Disease&amp;author=Z.%20M.%20Younossi&amp;author=M.%20Kalligeros&amp;author=L.%20Henry&amp;volume=31&amp;issue=Suppl&amp;publication_year=2025&amp;pages=S32-S50&amp;pmid=39159948&amp;doi=10.3350/cmh.2024.0431&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0002">
<span class="label">2.</span><cite>
Feng G., Targher G., Byrne C. D., et al., “Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease, 2010 to 2021,” JHEP Reports [Internet]
7, no. 3 (2025): 101271.
</cite> [<a href="https://doi.org/10.1016/j.jhepr.2024.101271" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11840544/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39980749/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JHEP%20Reports%20%5BInternet%5D&amp;title=Global%20Burden%20of%20Metabolic%20Dysfunction%E2%80%90Associated%20Steatotic%20Liver%20Disease,%202010%20to%202021&amp;author=G.%20Feng&amp;author=G.%20Targher&amp;author=C.%20D.%20Byrne&amp;volume=7&amp;issue=3&amp;publication_year=2025&amp;pages=101271&amp;pmid=39980749&amp;doi=10.1016/j.jhepr.2024.101271&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0003">
<span class="label">3.</span><cite>
Targher G., Tilg H., and Byrne C. D., “Non‐Alcoholic Fatty Liver Disease: A Multisystem Disease Requiring a Multidisciplinary and Holistic Approach,” Lancet Gastroenterology &amp; Hepatology
6, no. 7 (2021): 578–588.
</cite> [<a href="https://doi.org/10.1016/S2468-1253(21)00020-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33961787/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Gastroenterology%20&amp;%20Hepatology&amp;title=Non%E2%80%90Alcoholic%20Fatty%20Liver%20Disease:%20A%20Multisystem%20Disease%20Requiring%20a%20Multidisciplinary%20and%20Holistic%20Approach&amp;author=G.%20Targher&amp;author=H.%20Tilg&amp;author=C.%20D.%20Byrne&amp;volume=6&amp;issue=7&amp;publication_year=2021&amp;pages=578-588&amp;pmid=33961787&amp;doi=10.1016/S2468-1253(21)00020-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0004">
<span class="label">4.</span><cite>
Tilg H., Byrne C. D., and Targher G., “NASH Drug Treatment Development: Challenges and Lessons,” Lancet Gastroenterology &amp; Hepatology
8, no. 10 (2023): 943–954.
</cite> [<a href="https://doi.org/10.1016/S2468-1253(23)00159-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37597527/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Gastroenterology%20&amp;%20Hepatology&amp;title=NASH%20Drug%20Treatment%20Development:%20Challenges%20and%20Lessons&amp;author=H.%20Tilg&amp;author=C.%20D.%20Byrne&amp;author=G.%20Targher&amp;volume=8&amp;issue=10&amp;publication_year=2023&amp;pages=943-954&amp;pmid=37597527&amp;doi=10.1016/S2468-1253(23)00159-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0005">
<span class="label">5.</span><cite>
Targher G., Byrne C. D., and Tilg H., “MASLD: A Systemic Metabolic Disorder With Cardiovascular and Malignant Complications,” Gut
73, no. 4 (2024): 691–702.
</cite> [<a href="https://doi.org/10.1136/gutjnl-2023-330595" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38228377/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut&amp;title=MASLD:%20A%20Systemic%20Metabolic%20Disorder%20With%20Cardiovascular%20and%20Malignant%20Complications&amp;author=G.%20Targher&amp;author=C.%20D.%20Byrne&amp;author=H.%20Tilg&amp;volume=73&amp;issue=4&amp;publication_year=2024&amp;pages=691-702&amp;pmid=38228377&amp;doi=10.1136/gutjnl-2023-330595&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0006">
<span class="label">6.</span><cite>
Petta S., Targher G., Romeo S., et al., “The First MASH Drug Therapy on the Horizon: Current Perspectives of Resmetirom,” Liver International
44, no. 7 (2024): 1526–1536.
</cite> [<a href="https://doi.org/10.1111/liv.15930" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38578141/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20International&amp;title=The%20First%20MASH%20Drug%20Therapy%20on%20the%20Horizon:%20Current%20Perspectives%20of%20Resmetirom&amp;author=S.%20Petta&amp;author=G.%20Targher&amp;author=S.%20Romeo&amp;volume=44&amp;issue=7&amp;publication_year=2024&amp;pages=1526-1536&amp;pmid=38578141&amp;doi=10.1111/liv.15930&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0007">
<span class="label">7.</span><cite>
Au K., Zheng M. H., Lee W. J., et al., “Resmetirom and Metabolic Dysfunction‐Associated Steatohepatitis: Perspectives on Multidisciplinary Management From Global Healthcare Professionals,” Current Obesity Reports
13, no. 4 (2024): 818–830.
</cite> [<a href="https://doi.org/10.1007/s13679-024-00582-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39110384/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Obesity%20Reports&amp;title=Resmetirom%20and%20Metabolic%20Dysfunction%E2%80%90Associated%20Steatohepatitis:%20Perspectives%20on%20Multidisciplinary%20Management%20From%20Global%20Healthcare%20Professionals&amp;author=K.%20Au&amp;author=M.%20H.%20Zheng&amp;author=W.%20J.%20Lee&amp;volume=13&amp;issue=4&amp;publication_year=2024&amp;pages=818-830&amp;pmid=39110384&amp;doi=10.1007/s13679-024-00582-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0008">
<span class="label">8.</span><cite>
Byrne C. D., Targher G., and Tilg H., “Thyroid Hormone Receptor‐Beta Agonists: New MASLD Therapies on the Horizon,” Gut
73, no. 4 (2024): 573–581.
</cite> [<a href="https://doi.org/10.1136/gutjnl-2023-330596" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38233199/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut&amp;title=Thyroid%20Hormone%20Receptor%E2%80%90Beta%20Agonists:%20New%20MASLD%20Therapies%20on%20the%20Horizon&amp;author=C.%20D.%20Byrne&amp;author=G.%20Targher&amp;author=H.%20Tilg&amp;volume=73&amp;issue=4&amp;publication_year=2024&amp;pages=573-581&amp;pmid=38233199&amp;doi=10.1136/gutjnl-2023-330596&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0009">
<span class="label">9.</span><cite>
Sattar N., Lee M. M. Y., Kristensen S. L., et al., “Cardiovascular, Mortality, and Kidney Outcomes With GLP‐1 Receptor Agonists in Patients With Type 2 Diabetes: A Systematic Review and Meta‐Analysis of Randomised Trials,” Lancet. Diabetes &amp; Endocrinology
9, no. 10 (2021): 653–662.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(21)00203-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34425083/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet.%20Diabetes%20&amp;%20Endocrinology&amp;title=Cardiovascular,%20Mortality,%20and%20Kidney%20Outcomes%20With%20GLP%E2%80%901%20Receptor%20Agonists%20in%20Patients%20With%20Type%202%20Diabetes:%20A%20Systematic%20Review%20and%20Meta%E2%80%90Analysis%20of%20Randomised%20Trials&amp;author=N.%20Sattar&amp;author=M.%20M.%20Y.%20Lee&amp;author=S.%20L.%20Kristensen&amp;volume=9&amp;issue=10&amp;publication_year=2021&amp;pages=653-662&amp;pmid=34425083&amp;doi=10.1016/S2213-8587(21)00203-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0010">
<span class="label">10.</span><cite>
Badve S. V., Bilal A., Lee M. M. Y., et al., “Effects of GLP‐1 Receptor Agonists on Kidney and Cardiovascular Disease Outcomes: A Meta‐Analysis of Randomised Controlled Trials,” Lancet Diabetes &amp; Endocrinology
13, no. 1 (2025): 15–28.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(24)00271-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39608381/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Diabetes%20&amp;%20Endocrinology&amp;title=Effects%20of%20GLP%E2%80%901%20Receptor%20Agonists%20on%20Kidney%20and%20Cardiovascular%20Disease%20Outcomes:%20A%20Meta%E2%80%90Analysis%20of%20Randomised%20Controlled%20Trials&amp;author=S.%20V.%20Badve&amp;author=A.%20Bilal&amp;author=M.%20M.%20Y.%20Lee&amp;volume=13&amp;issue=1&amp;publication_year=2025&amp;pages=15-28&amp;pmid=39608381&amp;doi=10.1016/S2213-8587(24)00271-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0011">
<span class="label">11.</span><cite>
Lee M. M. Y., Ghouri N., Misra A., et al., “Comparative Efficacy of Glucagon‐Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta‐Analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity,” Diabetes Care
48, no. 3 (2025): 489–493.
</cite> [<a href="https://doi.org/10.2337/dc24-1533" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12081317/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39977628/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=Comparative%20Efficacy%20of%20Glucagon%E2%80%90Like%20Peptide%201%20Receptor%20Agonists%20for%20Cardiovascular%20Outcomes%20in%20Asian%20Versus%20White%20Populations:%20Systematic%20Review%20and%20Meta%E2%80%90Analysis%20of%20Randomized%20Trials%20of%20Populations%20With%20or%20Without%20Type%202%20Diabetes%20and/or%20Overweight%20or%20Obesity&amp;author=M.%20M.%20Y.%20Lee&amp;author=N.%20Ghouri&amp;author=A.%20Misra&amp;volume=48&amp;issue=3&amp;publication_year=2025&amp;pages=489-493&amp;pmid=39977628&amp;doi=10.2337/dc24-1533&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0012">
<span class="label">12.</span><cite>
Mannucci E., Gallo M., Giaccari A., et al., “Effects of Glucose‐Lowering Agents on Cardiovascular and Renal Outcomes in Subjects With Type 2 Diabetes: An Updated Meta‐Analysis of Randomized Controlled Trials With External Adjudication of Events,” Diabetes, Obesity &amp; Metabolism
25, no. 2 (2023): 444–453.</cite> [<a href="https://doi.org/10.1111/dom.14888" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36205446/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes,%20Obesity%20&amp;%20Metabolism&amp;title=Effects%20of%20Glucose%E2%80%90Lowering%20Agents%20on%20Cardiovascular%20and%20Renal%20Outcomes%20in%20Subjects%20With%20Type%202%20Diabetes:%20An%20Updated%20Meta%E2%80%90Analysis%20of%20Randomized%20Controlled%20Trials%20With%20External%20Adjudication%20of%20Events&amp;author=E.%20Mannucci&amp;author=M.%20Gallo&amp;author=A.%20Giaccari&amp;volume=25&amp;issue=2&amp;publication_year=2023&amp;pages=444-453&amp;pmid=36205446&amp;doi=10.1111/dom.14888&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0013">
<span class="label">13.</span><cite>
Mantovani A., Petracca G., Beatrice G., Csermely A., Lonardo A., and Targher G., “Glucagon‐Like Peptide‐1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta‐Analysis of Randomized Controlled Trials,” Metabolites
11, no. 2 (2021): 73.
</cite> [<a href="https://doi.org/10.3390/metabo11020073" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7911747/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33513761/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Metabolites&amp;title=Glucagon%E2%80%90Like%20Peptide%E2%80%901%20Receptor%20Agonists%20for%20Treatment%20of%20Nonalcoholic%20Fatty%20Liver%20Disease%20and%20Nonalcoholic%20Steatohepatitis:%20An%20Updated%20Meta%E2%80%90Analysis%20of%20Randomized%20Controlled%20Trials&amp;author=A.%20Mantovani&amp;author=G.%20Petracca&amp;author=G.%20Beatrice&amp;author=A.%20Csermely&amp;author=A.%20Lonardo&amp;volume=11&amp;issue=2&amp;publication_year=2021&amp;pages=73&amp;pmid=33513761&amp;doi=10.3390/metabo11020073&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0014">
<span class="label">14.</span><cite>
Fang L., Li J., Zeng H., and Liu J., “Effects of GLP‐1 Receptor Agonists on the Degree of Liver Fibrosis and CRP in Non‐Alcoholic Fatty Liver Disease and Non‐Alcoholic Steatohepatitis: A Systematic Review and Meta‐Analysis,” Primary Care Diabetes
18, no. 3 (2024): 268–276.
</cite> [<a href="https://doi.org/10.1016/j.pcd.2024.03.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38555202/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Primary%20Care%20Diabetes&amp;title=Effects%20of%20GLP%E2%80%901%20Receptor%20Agonists%20on%20the%20Degree%20of%20Liver%20Fibrosis%20and%20CRP%20in%20Non%E2%80%90Alcoholic%20Fatty%20Liver%20Disease%20and%20Non%E2%80%90Alcoholic%20Steatohepatitis:%20A%20Systematic%20Review%20and%20Meta%E2%80%90Analysis&amp;author=L.%20Fang&amp;author=J.%20Li&amp;author=H.%20Zeng&amp;author=J.%20Liu&amp;volume=18&amp;issue=3&amp;publication_year=2024&amp;pages=268-276&amp;pmid=38555202&amp;doi=10.1016/j.pcd.2024.03.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0015">
<span class="label">15.</span><cite>
Sanyal A. J., Newsome P. N., Kliers I., et al., “Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis,” New England Journal of Medicine
392, no. 21 (2025): 2089–2099.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2413258" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40305708/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Phase%203%20Trial%20of%20Semaglutide%20in%20Metabolic%20Dysfunction%E2%80%93Associated%20Steatohepatitis&amp;author=A.%20J.%20Sanyal&amp;author=P.%20N.%20Newsome&amp;author=I.%20Kliers&amp;volume=392&amp;issue=21&amp;publication_year=2025&amp;pages=2089-2099&amp;pmid=40305708&amp;doi=10.1056/NEJMoa2413258&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0016">
<span class="label">16.</span><cite>
Higgins J. P. T., Altman D. G., Gøtzsche P. C., et al., “The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials,” BMJ (Clinical Research Ed.)
343 (2011): d5928.</cite> [<a href="https://doi.org/10.1136/bmj.d5928" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3196245/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22008217/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ%20(Clinical%20Research%20Ed.)&amp;title=The%20Cochrane%20Collaboration's%20Tool%20for%20Assessing%20Risk%20of%20Bias%20in%20Randomised%20Trials&amp;author=J.%20P.%20T.%20Higgins&amp;author=D.%20G.%20Altman&amp;author=P.%20C.%20G%C3%B8tzsche&amp;volume=343&amp;publication_year=2011&amp;pages=d5928&amp;pmid=22008217&amp;doi=10.1136/bmj.d5928&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0017">
<span class="label">17.</span><cite>
Page M. J., McKenzie J. E., Bossuyt P. M., et al., “The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews,” BMJ (Clinical Research Ed.)
372 (2021): n71.</cite> [<a href="https://doi.org/10.1136/bmj.n71" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8005924/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33782057/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ%20(Clinical%20Research%20Ed.)&amp;title=The%20PRISMA%202020%20Statement:%20An%20Updated%20Guideline%20for%20Reporting%20Systematic%20Reviews&amp;author=M.%20J.%20Page&amp;author=J.%20E.%20McKenzie&amp;author=P.%20M.%20Bossuyt&amp;volume=372&amp;publication_year=2021&amp;pages=n71&amp;pmid=33782057&amp;doi=10.1136/bmj.n71&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0018">
<span class="label">18.</span><cite>
Higgins J. P. T. and Thompson S. G., “Quantifying Heterogeneity in a Meta‐Analysis,” Statistics in Medicine
21, no. 11 (2002): 1539–1558.
</cite> [<a href="https://doi.org/10.1002/sim.1186" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12111919/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Statistics%20in%20Medicine&amp;title=Quantifying%20Heterogeneity%20in%20a%20Meta%E2%80%90Analysis&amp;author=J.%20P.%20T.%20Higgins&amp;author=S.%20G.%20Thompson&amp;volume=21&amp;issue=11&amp;publication_year=2002&amp;pages=1539-1558&amp;pmid=12111919&amp;doi=10.1002/sim.1186&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0019">
<span class="label">19.</span><cite>
Dutour A., Abdesselam I., Ancel P., et al., “Exenatide Decreases Liver Fat Content and Epicardial Adipose Tissue in Patients With Obesity and Type 2 Diabetes: A Prospective Randomized Clinical Trial Using Magnetic Resonance Imaging and Spectroscopy,” Diabetes, Obesity &amp; Metabolism
18, no. 9 (2016): 882–891.</cite> [<a href="https://doi.org/10.1111/dom.12680" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27106272/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes,%20Obesity%20&amp;%20Metabolism&amp;title=Exenatide%20Decreases%20Liver%20Fat%20Content%20and%20Epicardial%20Adipose%20Tissue%20in%20Patients%20With%20Obesity%20and%20Type%202%20Diabetes:%20A%20Prospective%20Randomized%20Clinical%20Trial%20Using%20Magnetic%20Resonance%20Imaging%20and%20Spectroscopy&amp;author=A.%20Dutour&amp;author=I.%20Abdesselam&amp;author=P.%20Ancel&amp;volume=18&amp;issue=9&amp;publication_year=2016&amp;pages=882-891&amp;pmid=27106272&amp;doi=10.1111/dom.12680&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0020">
<span class="label">20.</span><cite>
Frøssing S., Nylander M., Chabanova E., et al., “Effect of Liraglutide on Ectopic Fat in Polycystic Ovary Syndrome: A Randomized Clinical Trial,” Diabetes, Obesity and Metabolism
20, no. 1 (2018): 215–218.</cite> [<a href="https://doi.org/10.1111/dom.13053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28681988/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes,%20Obesity%20and%20Metabolism&amp;title=Effect%20of%20Liraglutide%20on%20Ectopic%20Fat%20in%20Polycystic%20Ovary%20Syndrome:%20A%20Randomized%20Clinical%20Trial&amp;author=S.%20Fr%C3%B8ssing&amp;author=M.%20Nylander&amp;author=E.%20Chabanova&amp;volume=20&amp;issue=1&amp;publication_year=2018&amp;pages=215-218&amp;pmid=28681988&amp;doi=10.1111/dom.13053&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0021">
<span class="label">21.</span><cite>
Yan J., Yao B., Kuang H., et al., “Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease,” Hepatology
69, no. 6 (2019): 2414–2426.
</cite> [<a href="https://doi.org/10.1002/hep.30320" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6594101/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30341767/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Liraglutide,%20Sitagliptin,%20and%20Insulin%20Glargine%20Added%20to%20Metformin:%20The%20Effect%20on%20Body%20Weight%20and%20Intrahepatic%20Lipid%20in%20Patients%20With%20Type%202%20Diabetes%20Mellitus%20and%20Nonalcoholic%20Fatty%20Liver%20Disease&amp;author=J.%20Yan&amp;author=B.%20Yao&amp;author=H.%20Kuang&amp;volume=69&amp;issue=6&amp;publication_year=2019&amp;pages=2414-2426&amp;pmid=30341767&amp;doi=10.1002/hep.30320&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0022">
<span class="label">22.</span><cite>
Khoo J., Hsiang J. C., Taneja R., et al., “Randomized Trial Comparing Effects of Weight Loss by Liraglutide With Lifestyle Modification in Non‐Alcoholic Fatty Liver Disease,” Liver International
39, no. 5 (2019): 941–949.
</cite> [<a href="https://doi.org/10.1111/liv.14065" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30721572/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20International&amp;title=Randomized%20Trial%20Comparing%20Effects%20of%20Weight%20Loss%20by%20Liraglutide%20With%20Lifestyle%20Modification%20in%20Non%E2%80%90Alcoholic%20Fatty%20Liver%20Disease&amp;author=J.%20Khoo&amp;author=J.%20C.%20Hsiang&amp;author=R.%20Taneja&amp;volume=39&amp;issue=5&amp;publication_year=2019&amp;pages=941-949&amp;pmid=30721572&amp;doi=10.1111/liv.14065&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0023">
<span class="label">23.</span><cite>
Liu L., Yan H., Xia M., et al., “Efficacy of Exenatide and Insulin Glargine on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes,” Diabetes/Metabolism Research and Reviews
36, no. 5 (2020): e3292.
</cite> [<a href="https://doi.org/10.1002/dmrr.3292" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31955491/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes/Metabolism%20Research%20and%20Reviews&amp;title=Efficacy%20of%20Exenatide%20and%20Insulin%20Glargine%20on%20Nonalcoholic%20Fatty%20Liver%20Disease%20in%20Patients%20With%20Type%202%20Diabetes&amp;author=L.%20Liu&amp;author=H.%20Yan&amp;author=M.%20Xia&amp;volume=36&amp;issue=5&amp;publication_year=2020&amp;pages=e3292&amp;pmid=31955491&amp;doi=10.1002/dmrr.3292&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0024">
<span class="label">24.</span><cite>
Bizino M. B., Jazet I. M., de Heer P., et al., “Placebo‐Controlled Randomised Trial With Liraglutide on Magnetic Resonance Endpoints in Individuals With Type 2 Diabetes: A Pre‐Specified Secondary Study on Ectopic Fat Accumulation,” Diabetologia
63, no. 1 (2020): 65–74.
</cite> [<a href="https://doi.org/10.1007/s00125-019-05021-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6890592/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31690988/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetologia&amp;title=Placebo%E2%80%90Controlled%20Randomised%20Trial%20With%20Liraglutide%20on%20Magnetic%20Resonance%20Endpoints%20in%20Individuals%20With%20Type%202%20Diabetes:%20A%20Pre%E2%80%90Specified%20Secondary%20Study%20on%20Ectopic%20Fat%20Accumulation&amp;author=M.%20B.%20Bizino&amp;author=I.%20M.%20Jazet&amp;author=P.%20de%20Heer&amp;volume=63&amp;issue=1&amp;publication_year=2020&amp;pages=65-74&amp;pmid=31690988&amp;doi=10.1007/s00125-019-05021-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0025">
<span class="label">25.</span><cite>
Kuchay M. S., Krishan S., Mishra S. K., et al., “Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and NAFLD: Randomised Controlled Trial (D‐LIFT Trial),” Diabetologia
63, no. 11 (2020): 2434–2445.
</cite> [<a href="https://doi.org/10.1007/s00125-020-05265-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32865597/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetologia&amp;title=Effect%20of%20Dulaglutide%20on%20Liver%20Fat%20in%20Patients%20With%20Type%202%20Diabetes%20and%20NAFLD:%20Randomised%20Controlled%20Trial%20(D%E2%80%90LIFT%20Trial)&amp;author=M.%20S.%20Kuchay&amp;author=S.%20Krishan&amp;author=S.%20K.%20Mishra&amp;volume=63&amp;issue=11&amp;publication_year=2020&amp;pages=2434-2445&amp;pmid=32865597&amp;doi=10.1007/s00125-020-05265-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0026">
<span class="label">26.</span><cite>
Guo W., Tian W., Lin L., and Xu X., “Liraglutide or Insulin Glargine Treatments Improves Hepatic Fat in Obese Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease in Twenty‐Six Weeks: A Randomized Placebo‐Controlled Trial,” Diabetes Research and Clinical Practice [Internet]
170 (2020): 108487.
</cite> [<a href="https://doi.org/10.1016/j.diabres.2020.108487" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33035599/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Research%20and%20Clinical%20Practice%20%5BInternet%5D&amp;title=Liraglutide%20or%20Insulin%20Glargine%20Treatments%20Improves%20Hepatic%20Fat%20in%20Obese%20Patients%20With%20Type%202%20Diabetes%20and%20Nonalcoholic%20Fatty%20Liver%20Disease%20in%20Twenty%E2%80%90Six%20Weeks:%20A%20Randomized%20Placebo%E2%80%90Controlled%20Trial&amp;author=W.%20Guo&amp;author=W.%20Tian&amp;author=L.%20Lin&amp;author=X.%20Xu&amp;volume=170&amp;publication_year=2020&amp;pages=108487&amp;pmid=33035599&amp;doi=10.1016/j.diabres.2020.108487&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0027">
<span class="label">27.</span><cite>
Flint A., Andersen G., Hockings P., et al., “Randomised Clinical Trial: Semaglutide Versus Placebo Reduced Liver Steatosis but Not Liver Stiffness in Subjects With Non‐Alcoholic Fatty Liver Disease Assessed by Magnetic Resonance Imaging,” Alimentary Pharmacology &amp; Therapeutics
54, no. 9 (2021): 1150–1161.
</cite> [<a href="https://doi.org/10.1111/apt.16608" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9292692/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34570916/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Alimentary%20Pharmacology%20&amp;%20Therapeutics&amp;title=Randomised%20Clinical%20Trial:%20Semaglutide%20Versus%20Placebo%20Reduced%20Liver%20Steatosis%20but%20Not%20Liver%20Stiffness%20in%20Subjects%20With%20Non%E2%80%90Alcoholic%20Fatty%20Liver%20Disease%20Assessed%20by%20Magnetic%20Resonance%20Imaging&amp;author=A.%20Flint&amp;author=G.%20Andersen&amp;author=P.%20Hockings&amp;volume=54&amp;issue=9&amp;publication_year=2021&amp;pages=1150-1161&amp;pmid=34570916&amp;doi=10.1111/apt.16608&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0028">
<span class="label">28.</span><cite>
Armstrong M. J., Gaunt P., Aithal G. P., et al., “Liraglutide Safety and Efficacy in Patients With Non‐Alcoholic Steatohepatitis (LEAN): A Multicentre, Double‐Blind, Randomised, Placebo‐Controlled Phase 2 Study,” Lancet
387, no. 10019 (2016): 679–690.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(15)00803-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26608256/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Liraglutide%20Safety%20and%20Efficacy%20in%20Patients%20With%20Non%E2%80%90Alcoholic%20Steatohepatitis%20(LEAN):%20A%20Multicentre,%20Double%E2%80%90Blind,%20Randomised,%20Placebo%E2%80%90Controlled%20Phase%202%20Study&amp;author=M.%20J.%20Armstrong&amp;author=P.%20Gaunt&amp;author=G.%20P.%20Aithal&amp;volume=387&amp;issue=10019&amp;publication_year=2016&amp;pages=679-690&amp;pmid=26608256&amp;doi=10.1016/S0140-6736(15)00803-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0029">
<span class="label">29.</span><cite>
Newsome P. N., Buchholtz K., Cusi K., et al., “A Placebo‐Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis,” New England Journal of Medicine
384, no. 12 (2021): 1113–1124.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2028395" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33185364/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=A%20Placebo%E2%80%90Controlled%20Trial%20of%20Subcutaneous%20Semaglutide%20in%20Nonalcoholic%20Steatohepatitis&amp;author=P.%20N.%20Newsome&amp;author=K.%20Buchholtz&amp;author=K.%20Cusi&amp;volume=384&amp;issue=12&amp;publication_year=2021&amp;pages=1113-1124&amp;pmid=33185364&amp;doi=10.1056/NEJMoa2028395&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0030">
<span class="label">30.</span><cite>
Loomba R., Abdelmalek M. F., Armstrong M. J., et al., “Semaglutide 2·4 Mg Once Weekly in Patients With Non‐Alcoholic Steatohepatitis‐Related Cirrhosis: A Randomised, Placebo‐Controlled Phase 2 Trial,” Lancet Gastroenterology &amp; Hepatology
8, no. 6 (2023): 511–522.
</cite> [<a href="https://doi.org/10.1016/S2468-1253(23)00068-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10792518/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36934740/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Gastroenterology%20&amp;%20Hepatology&amp;title=Semaglutide%202%C2%B74%20Mg%20Once%20Weekly%20in%20Patients%20With%20Non%E2%80%90Alcoholic%20Steatohepatitis%E2%80%90Related%20Cirrhosis:%20A%20Randomised,%20Placebo%E2%80%90Controlled%20Phase%202%20Trial&amp;author=R.%20Loomba&amp;author=M.%20F.%20Abdelmalek&amp;author=M.%20J.%20Armstrong&amp;volume=8&amp;issue=6&amp;publication_year=2023&amp;pages=511-522&amp;pmid=36934740&amp;doi=10.1016/S2468-1253(23)00068-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0031">
<span class="label">31.</span><cite>
Mantovani A., Lonardo A., Stefan N., and Targher G., “Metabolic Dysfunction‐Associated Steatotic Liver Disease and Extrahepatic Gastrointestinal Cancers,” Metabolism: Clinical and Experimental
160 (2024): 156014.
</cite> [<a href="https://doi.org/10.1016/j.metabol.2024.156014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39182602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Metabolism:%20Clinical%20and%20Experimental&amp;title=Metabolic%20Dysfunction%E2%80%90Associated%20Steatotic%20Liver%20Disease%20and%20Extrahepatic%20Gastrointestinal%20Cancers&amp;author=A.%20Mantovani&amp;author=A.%20Lonardo&amp;author=N.%20Stefan&amp;author=G.%20Targher&amp;volume=160&amp;publication_year=2024&amp;pages=156014&amp;pmid=39182602&amp;doi=10.1016/j.metabol.2024.156014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0032">
<span class="label">32.</span><cite>
Lin R. T., Sun Q. M., Xin X., et al., “Comparative Efficacy of THR‐β Agonists, FGF‐21 Analogues, GLP‐1R Agonists, GLP‐1‐Based Polyagonists, and Pan‐PPAR Agonists for MASLD: A Systematic Review and Network Meta‐Analysis,” Metabolism: Clinical and Experimental
161 (2024): 156043.
</cite> [<a href="https://doi.org/10.1016/j.metabol.2024.156043" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39357599/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Metabolism:%20Clinical%20and%20Experimental&amp;title=Comparative%20Efficacy%20of%20THR%E2%80%90%CE%B2%20Agonists,%20FGF%E2%80%9021%20Analogues,%20GLP%E2%80%901R%20Agonists,%20GLP%E2%80%901%E2%80%90Based%20Polyagonists,%20and%20Pan%E2%80%90PPAR%20Agonists%20for%20MASLD:%20A%20Systematic%20Review%20and%20Network%20Meta%E2%80%90Analysis&amp;author=R.%20T.%20Lin&amp;author=Q.%20M.%20Sun&amp;author=X.%20Xin&amp;volume=161&amp;publication_year=2024&amp;pages=156043&amp;pmid=39357599&amp;doi=10.1016/j.metabol.2024.156043&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0033">
<span class="label">33.</span><cite>
Souza M., Al‐Sharif L., Antunes V. L. J., Huang D. Q., and Loomba R., “Comparison of Pharmacological Therapies in Metabolic Dysfunction–Associated Steatohepatitis for Fibrosis Regression and MASH Resolution: Systematic Review and Network Meta‐Analysis,” Hepatology (2025), 10.1097/HEP.0000000000001254.</cite> [<a href="https://doi.org/10.1097/HEP.0000000000001254" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39903735/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Comparison%20of%20Pharmacological%20Therapies%20in%20Metabolic%20Dysfunction%E2%80%93Associated%20Steatohepatitis%20for%20Fibrosis%20Regression%20and%20MASH%20Resolution:%20Systematic%20Review%20and%20Network%20Meta%E2%80%90Analysis&amp;author=M.%20Souza&amp;author=L.%20Al%E2%80%90Sharif&amp;author=V.%20L.%20J.%20Antunes&amp;author=D.%20Q.%20Huang&amp;author=R.%20Loomba&amp;publication_year=2025&amp;pmid=39903735&amp;doi=10.1097/HEP.0000000000001254&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0034">
<span class="label">34.</span><cite>
Xu R., Liu B., and Zhou X., “Comparison of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Cotransporter Protein‐2 Inhibitors on Treating Metabolic Dysfunction‐Associated Steatotic Liver Disease or Metabolic Dysfunction‐Associated Steatohepatitis: Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials,” Endocrine Practice
31, no. 4 (2025): 521–535.
</cite> [<a href="https://doi.org/10.1016/j.eprac.2024.11.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39701283/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Endocrine%20Practice&amp;title=Comparison%20of%20Glucagon%E2%80%90Like%20Peptide%E2%80%901%20Receptor%20Agonists%20and%20Sodium%E2%80%90Glucose%20Cotransporter%20Protein%E2%80%902%20Inhibitors%20on%20Treating%20Metabolic%20Dysfunction%E2%80%90Associated%20Steatotic%20Liver%20Disease%20or%20Metabolic%20Dysfunction%E2%80%90Associated%20Steatohepatitis:%20Systematic%20Review%20and%20Network%20Meta%E2%80%90Analysis%20of%20Randomised%20Controlled%20Trials&amp;author=R.%20Xu&amp;author=B.%20Liu&amp;author=X.%20Zhou&amp;volume=31&amp;issue=4&amp;publication_year=2025&amp;pages=521-535&amp;pmid=39701283&amp;doi=10.1016/j.eprac.2024.11.017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0035">
<span class="label">35.</span><cite>
Wang Y., Zhou Y., Wang Z., Ni Y., Prud'homme G. J., and Wang Q., “Efficacy of GLP‐1‐Based Therapies on Metabolic Dysfunction‐Associated Steatotic Liver Disease and Metabolic Dysfunction‐Associated Steatohepatitis: A Systematic Review and Meta‐Analysis,” Journal of Clinical Endocrinology and Metabolism (2025): dgaf336.
</cite> [<a href="https://doi.org/10.1210/clinem/dgaf336" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40489581/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Endocrinology%20and%20Metabolism&amp;title=Efficacy%20of%20GLP%E2%80%901%E2%80%90Based%20Therapies%20on%20Metabolic%20Dysfunction%E2%80%90Associated%20Steatotic%20Liver%20Disease%20and%20Metabolic%20Dysfunction%E2%80%90Associated%20Steatohepatitis:%20A%20Systematic%20Review%20and%20Meta%E2%80%90Analysis&amp;author=Y.%20Wang&amp;author=Y.%20Zhou&amp;author=Z.%20Wang&amp;author=Y.%20Ni&amp;author=G.%20J.%20Prud'homme&amp;publication_year=2025&amp;pages=dgaf336&amp;pmid=40489581&amp;doi=10.1210/clinem/dgaf336&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0036">
<span class="label">36.</span><cite>
Newsome P. N., Sanyal A. J., Engebretsen K. A., et al., “Semaglutide 2.4 Mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial,” Alimentary Pharmacology &amp; Therapeutics
60, no. 11–12 (2024): 1525–1533.
</cite> [<a href="https://doi.org/10.1111/apt.18331" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11599791/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39412509/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Alimentary%20Pharmacology%20&amp;%20Therapeutics&amp;title=Semaglutide%202.4%20Mg%20in%20Participants%20With%20Metabolic%20Dysfunction%E2%80%90Associated%20Steatohepatitis:%20Baseline%20Characteristics%20and%20Design%20of%20the%20Phase%203%20ESSENCE%20Trial&amp;author=P.%20N.%20Newsome&amp;author=A.%20J.%20Sanyal&amp;author=K.%20A.%20Engebretsen&amp;volume=60&amp;issue=11%E2%80%9312&amp;publication_year=2024&amp;pages=1525-1533&amp;pmid=39412509&amp;doi=10.1111/apt.18331&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0037">
<span class="label">37.</span><cite>
Celsa C., Pennisi G., Tulone A., et al., “Glucagon‐Like Peptide‐1 Receptor Agonist Use Is Associated With a Lower Risk of Major Adverse Liver‐Related Outcomes: A Meta‐Analysis of Observational Cohort Studies,” Gut
74, no. 5 (2025): 815–824.
</cite> [<a href="https://doi.org/10.1136/gutjnl-2024-334591" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40015951/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut&amp;title=Glucagon%E2%80%90Like%20Peptide%E2%80%901%20Receptor%20Agonist%20Use%20Is%20Associated%20With%20a%20Lower%20Risk%20of%20Major%20Adverse%20Liver%E2%80%90Related%20Outcomes:%20A%20Meta%E2%80%90Analysis%20of%20Observational%20Cohort%20Studies&amp;author=C.%20Celsa&amp;author=G.%20Pennisi&amp;author=A.%20Tulone&amp;volume=74&amp;issue=5&amp;publication_year=2025&amp;pages=815-824&amp;pmid=40015951&amp;doi=10.1136/gutjnl-2024-334591&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0038">
<span class="label">38.</span><cite>
American Diabetes Association Professional Practice Committee
, “Summary of Revisions: Standards of Care in Diabetes—2025,” Diabetes Care
48, no. Supplement_1 (2024): S6–S13.</cite> [<a href="https://doi.org/10.2337/dc25-SREV" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11635056/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39651984/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=Summary%20of%20Revisions:%20Standards%20of%20Care%20in%20Diabetes%E2%80%942025&amp;volume=48&amp;issue=Supplement_1&amp;publication_year=2024&amp;pages=S6-S13&amp;pmid=39651984&amp;doi=10.2337/dc25-SREV&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0039">
<span class="label">39.</span><cite>
Cusi K., Abdelmalek M. F., Apovian C. M., et al., “Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association,” Diabetes Care
48, no. 7 (2025): 1057–1082.
</cite> [<a href="https://doi.org/10.2337/dci24-0094" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40434108/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=Metabolic%20Dysfunction%E2%80%93Associated%20Steatotic%20Liver%20Disease%20(MASLD)%20in%20People%20With%20Diabetes:%20The%20Need%20for%20Screening%20and%20Early%20Intervention.%20A%20Consensus%20Report%20of%20the%20American%20Diabetes%20Association&amp;author=K.%20Cusi&amp;author=M.%20F.%20Abdelmalek&amp;author=C.%20M.%20Apovian&amp;volume=48&amp;issue=7&amp;publication_year=2025&amp;pages=1057-1082&amp;pmid=40434108&amp;doi=10.2337/dci24-0094&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0040">
<span class="label">40.</span><cite>
Stefan N., Yki‐Järvinen H., and Neuschwander‐Tetri B. A., “Metabolic Dysfunction‐Associated Steatotic Liver Disease: Heterogeneous Pathomechanisms and Effectiveness of Metabolism‐Based Treatment,” Lancet Diabetes &amp; Endocrinology [Internet]
13, no. 2 (2024): 134–148.
</cite> [<a href="https://doi.org/10.1016/S2213-8587(24)00318-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39681121/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Diabetes%20&amp;%20Endocrinology%20%5BInternet%5D&amp;title=Metabolic%20Dysfunction%E2%80%90Associated%20Steatotic%20Liver%20Disease:%20Heterogeneous%20Pathomechanisms%20and%20Effectiveness%20of%20Metabolism%E2%80%90Based%20Treatment&amp;author=N.%20Stefan&amp;author=H.%20Yki%E2%80%90J%C3%A4rvinen&amp;author=B.%20A.%20Neuschwander%E2%80%90Tetri&amp;volume=13&amp;issue=2&amp;publication_year=2024&amp;pages=134-148&amp;pmid=39681121&amp;doi=10.1016/S2213-8587(24)00318-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0041">
<span class="label">41.</span><cite>
Loomba R., Hartman M. L., Lawitz E. J., et al., “Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis With Liver Fibrosis,” New England Journal of Medicine
391, no. 4 (2024): 299–310.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2401943" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38856224/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Tirzepatide%20for%20Metabolic%20Dysfunction%E2%80%93Associated%20Steatohepatitis%20With%20Liver%20Fibrosis&amp;author=R.%20Loomba&amp;author=M.%20L.%20Hartman&amp;author=E.%20J.%20Lawitz&amp;volume=391&amp;issue=4&amp;publication_year=2024&amp;pages=299-310&amp;pmid=38856224&amp;doi=10.1056/NEJMoa2401943&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0042">
<span class="label">42.</span><cite>
Targher G., Mantovani A., Byrne C. D., and Tilg H., “Recent Advances in Incretin‐Based Therapy for MASLD: From Single to Dual or Triple Incretin Receptor Agonists,” Gut [Internet]
74, no. 3 (2024): 487–497.</cite> [<a href="https://doi.org/10.1136/gutjnl-2024-334023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39592207/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut%20%5BInternet%5D&amp;title=Recent%20Advances%20in%20Incretin%E2%80%90Based%20Therapy%20for%20MASLD:%20From%20Single%20to%20Dual%20or%20Triple%20Incretin%20Receptor%20Agonists&amp;author=G.%20Targher&amp;author=A.%20Mantovani&amp;author=C.%20D.%20Byrne&amp;author=H.%20Tilg&amp;volume=74&amp;issue=3&amp;publication_year=2024&amp;pages=487-497&amp;pmid=39592207&amp;doi=10.1136/gutjnl-2024-334023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0043">
<span class="label">43.</span><cite>
Targher G., Mantovani A., and Byrne C. D., “Mechanisms and Possible Hepatoprotective Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Other Incretin Receptor Agonists in Non‐Alcoholic Fatty Liver Disease,” Lancet Gastroenterology &amp; Hepatology
8, no. 2 (2023): 179–191.
</cite> [<a href="https://doi.org/10.1016/S2468-1253(22)00338-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36620987/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Gastroenterology%20&amp;%20Hepatology&amp;title=Mechanisms%20and%20Possible%20Hepatoprotective%20Effects%20of%20Glucagon%E2%80%90Like%20Peptide%E2%80%901%20Receptor%20Agonists%20and%20Other%20Incretin%20Receptor%20Agonists%20in%20Non%E2%80%90Alcoholic%20Fatty%20Liver%20Disease&amp;author=G.%20Targher&amp;author=A.%20Mantovani&amp;author=C.%20D.%20Byrne&amp;volume=8&amp;issue=2&amp;publication_year=2023&amp;pages=179-191&amp;pmid=36620987&amp;doi=10.1016/S2468-1253(22)00338-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0044">
<span class="label">44.</span><cite>
Castera L., Friedrich‐Rust M., and Loomba R., “Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease,” Gastroenterology
156, no. 5 (2019): 1264–1281.e4.
</cite> [<a href="https://doi.org/10.1053/j.gastro.2018.12.036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7505052/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30660725/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Noninvasive%20Assessment%20of%20Liver%20Disease%20in%20Patients%20With%20Nonalcoholic%20Fatty%20Liver%20Disease&amp;author=L.%20Castera&amp;author=M.%20Friedrich%E2%80%90Rust&amp;author=R.%20Loomba&amp;volume=156&amp;issue=5&amp;publication_year=2019&amp;pages=1264-1281.e4&amp;pmid=30660725&amp;doi=10.1053/j.gastro.2018.12.036&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="liv70256-bib-0045">
<span class="label">45.</span><cite>
Lonardo A., Nascimbeni F., Ballestri S., et al., “Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps,” Hepatology
70, no. 4 (2019): 1457–1469.
</cite> [<a href="https://doi.org/10.1002/hep.30626" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6766425/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30924946/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hepatology&amp;title=Sex%20Differences%20in%20Nonalcoholic%20Fatty%20Liver%20Disease:%20State%20of%20the%20Art%20and%20Identification%20of%20Research%20Gaps&amp;author=A.%20Lonardo&amp;author=F.%20Nascimbeni&amp;author=S.%20Ballestri&amp;volume=70&amp;issue=4&amp;publication_year=2019&amp;pages=1457-1469&amp;pmid=30924946&amp;doi=10.1002/hep.30626&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><p>
<strong>Data S1:</strong> liv70256‐sup‐0001‐supinfo.pdf.</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12309150/bin/LIV-45-0-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">LIV-45-0-s001.pdf</a><sup> (2MB, pdf) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data that supports the findings of this study are available in the <a href="#liv70256-supitem-0001" class="usa-link">Supporting Information</a> of this article.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Liver International are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1111/liv.70256"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/LIV-45-0.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (881.6 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12309150/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12309150/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12309150%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12309150/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12309150/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12309150/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40736113/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12309150/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40736113/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12309150/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12309150/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="B1QIeMrgbk6AqCqRtylXk8vy0EGTOzRLqMNPvta3LaNjSkfwzPFyatZs4HFi5HES">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
